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                                                               ABSTRACT 
This thesis research involved investigations into the effects of inflammation on 
maturation of L-carnitine homeostasis in developing rat neonates. The overall hypothesis was an 
inflammatory stimulus will alter the ontogeny of L-carnitine homeostasis pathways and this 
depends upon when the inflammatory stimulus occurs in postnatal development. The objective 
was to investigate the potential effect of inflammation on carnitine transporter expression in 
different age groups of neonates and evaluation of effect of inflammation on ontogeny and 
activity of enzymes involved in carnitine biosynthesis and whether this differs depending upon 
when in postnatal development the inflammatory stimulus occurs. 
Rat pups at postnatal day 3, 7, and 14 received an intraperitoneal injection of 
lipopolysaccharide (LPS) at a dose known to cause a febrile reaction in rat neonates. L-Carnitine 
homeostasis pathways underwent significant ontogenesis during postnatal development in the 
rat. LPS administration caused a significant decrease in free L-carnitine levels in serum and heart 
tissue and a decrease in mRNA expression levels of the high affinity carnitine transporter, Octn2, 
in kidney, heart and intestine at all postnatal ages. Furthermore, significant decreases in mRNA 
expression levels of key enzymes involved in carnitine biosynthesis was observed, while an 
increase in carnitine palmitoyltransferase mRNA levels were observed at all postnatal ages. 
Reductions in butyrobetaine hydroxylase mRNA expression were paralleled by reductions in 
enzyme activity only at postnatal day 3 and 7. Heart creatine phosphate levels were deceased 
significantly in LPS treated groups in all postnatal ages; however, ADP and ATP levels were 
unaffected. Collectively, this research provided experimental evidence for a significant effect of 
inflammation on changes in L-carnitine homeostasis maturation in early neonatal stages. The 
maturation of physiological processes may be altered by external factors in early postnatal life.  
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Chapter 1 
1. Introduction 
Carnitine (3-hydroxy-4-N-trimethylamino butyrate) is a low molecular weight, water 
soluble ubiquitous molecule that exists in nearly all plants (1), animals, and microorganisms (1, 
2). L-Carnitine is available as free L-carnitine (non esterified molecule; FC) and esterified 
derivatives (acylcarnitines; AC) in mammals (3, 4). Fatty acids are important energy metabolism 
substrates and mitochondrial β-oxidation of long chain fatty acids requires adequate amounts of 
L-carnitine. In neonates, L-carnitine has a crucial role in myocardial β-oxidation of long-chain 
fatty acids, elimination of toxic metabolites, ketogenesis, and regulation of nitrogen metabolism 
(5, 6).  
Neonates are particularly vulnerable to the development of L-carnitine deficiency and its 
associated physiological disorders since the biosynthetic enzymes and transporters responsible 
for maintenance of L-carnitine homeostasis undergo maturation in early stages of postnatal life. 
Neonates are often exposed to several acute pathological conditions while important 
physiological systems are still undergoing maturation. While much attention in neonatal 
therapeutics has focused on appropriate dosage regimens for this age group, less attention has 
been paid to understanding long-term and short-term effects of acute pathological conditions on 
the maturation of important physiological processes that may have a specific role in the 
development of chronic disease in later stages of life. Several pathological conditions can lead to 
inflammation during the neonatal stage and these conditions can alter the developmental program 
of physiological processes.  
This thesis work endeavours to advance our understanding of the possible effect of 
inflammation on maturation of L-carnitine homeostasis mechanisms in neonates. The effects of 
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an inflammatory stimulus on different elements of L-carnitine homeostasis at different stages of 
neonatal development will identify the influence of inflammatory disease on maturation of L-
carnitine homeostasis mechanisms.   
1.2. Literature Review  
1.2.1. Developmental Programming 
Developmental programming refers to characteristics of the environment that appear 
during fetal and neonatal development, which permanently alter the normal maturation of 
physiological and biochemical processes (7, 8). Developmental programming has the following 
characteristics: 1) Susceptibility of organism to external environment is restricted to a critical 
ontogenetic window during early development; 2) Persistent that continues into adult life; and 3) 
Unique and quantifiable result that can vary significantly among individuals. Several factors 
determine developmental programming including nutritional and disease states, environmental 
conditions, gynecological immaturity, and the maternal or fetal genotype (9).  
During early development, a window of plasticity exists, a period of time when the 
organism may still develop in various directions and has potential to adjust or adapt to its 
environment. Even though epidemiological research has mainly focused on the detrimental 
ramifications of programming, it is not predominantly an injurious phenomenon (10). The ability 
to adopt a phenotype to different conditions prevalent in early life is an important adaptive 
phenomenon particularly if the environment is comparatively stable. A mismatch between the 
environment in prenatal or early postnatal life and adult life may culminate in unsuitable 
adaptations in the organism (11-13). However, adjustments that occur in critical periods of 
maturation can also guarantee the preservation of homeostasis when the surroundings are 
jeopardised (10).   
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Substantial research has focused on prenatal (and to a lesser extent postnatal) nutritional 
status as this can have significant influence on the developing fetus and neonates (14). The 
developing system is highly adaptive to the available nutrition supply, a phenomenon referred to 
as nutritional programming (15, 16). When a discrepancy exists between early life nutrition and 
availability of macro- and micronutrients in adult life, the permanent alterations induced during 
nutritional programming may have detrimental consequences in adult life (15, 16). 
 
1.2.1.1 Evidence of programming during postnatal development   
 
Evidence for the ability of the environment in early life to increase risk for chronic disease 
in adult life emerged in ecological research that investigated the reasons for the north-south 
division of disease patterns in England and Wales (17). The research uncovered the importance 
of maternal nutritional state during fetal and neonatal development in coronary heart disease 
(CHD) (18). An augmented risk of CHD death, high blood pressure, type 2 diabetes, and 
metabolic syndrome was related to low birth weights (18). This is now termed the Barker theory 
where it is now widely accepted that fetal programming by nutritional stimuli or glucocorticoids 
(stress hormones) results in physiological adaptations of the fetus to its environment in utero to 
ensure its readiness for postnatal life (19). Data from the survivors of World War II and the 
Dutch Hunger Winter also provide clear evidence that malnutrition during neonatal development 
predisposes the offspring to risk of CHD, metabolic syndrome, diabetes, and other chronic 
diseases. A multitude of independent research in developed and developing countries have 
corroborated that chronic disease is connected with low birth weight and malnutrition during 
pregnancy (20, 21).   
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The notion of the effects of intrauterine life on adult health and on the incidence of late 
onset illnesses, such as hypertension and type II diabetes, is a comparatively more recent idea. 
Forsdahl and coworkers in 1977 reported that the incidence of arteriosclerotic heart disease in a 
particular age group could be associated with the degree of infant mortality of that same 
population (22). A few studies conducted in the 20th century showed that a relationship between 
birth weight and tendency of developing cardiovascular and metabolic diseases in adulthood (23) 
(24).  
Studies in primates demonstrate that over-nutrition during infancy in the female results in 
development of obesity in early adult life (25). Therefore, the question has been raised: “what is 
the place of epigenetic memory being stored in the intervening period?” Further research was 
conducted on baboons, which evaluated cholesterol levels on specific diets (26, 27). Higher 
plasma LDL and VLDL cholesterol, lower HDL cholesterol, and increased cholesterol was 
revealed in adult baboons that were breastfed in the early life as compared to bottle fed baboons 
suggesting primates may be programmed by breast-feeding (27). In fact, post-mortem 
evaluations showed that breastfed baboons had profoundly more atherosclerosis (26, 27). 
 
1.2.2 Epigenetics and its Importance during Postnatal Development 
 
It has become increasingly evident in recent years that development is under epigenetic 
control. Epigenetics explains the genetic modification in functions of genes which are 
independent of gene code or DNA sequences (28). Epigenetics defines changes in expression 
levels of functional genes over a particular period of time. According to the National Institutes of 
Health’s definition, epigenetics is the study of changes in the regulation of gene activity and 
expression that are not dependent on gene sequence (29, 30). Evidence is available that shows 
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changes in developmental programming due to altercations in epigenetics following from 
numerous external stimuli (29, 31-34).  
The relationship between the environmental conditions during development and 
developmental programming is very complex (35). Limited research has been conducted to 
identify the factors affecting the complex relationship between these mechanisms. The 
identification of links between external signals and the epigenetic machinery with specific 
physiological outcomes is an area of increasing importance because of its impact on 
developmental programming and child health (30, 36). Histone modifications and DNA 
methylation were two well studies mechanism in epigenetics. Only two of many factors, 
nutritional conditions and stress, have been studied and well documented.  It has been reported 
that these factors influence adult risk of developing metabolic disease, such as type 2 diabetes 
mellitus and cardiac diseases (37). High risk to develop cardiovascular morbidity and mortality 
during adult life is associated with individuals born small for gestational age (4 –7). This 
epidemiological evidence is now supported by an extensive experimental literature in animals. 
Evidence on the importance of prenatal and early postnatal growth for later morbidity suggests 
the existence of a link between developmental responses to early environments and adult 
biology. For instance, the roles of histone demethylases in the context of whole body physiology 
are now being uncovered (38, 39).  The histone demethylase, Jhdm2a, for instance, was recently 
identified as a crucial regulator of genes involved in energy expenditure and fat storage and, 
therefore, Jhdm2a may be a key factor in obesity and metabolic syndrome (38, 39).  
It is common knowledge in human history that a child’s development during the fetal and 
neonatal period is influenced by the environment and life events. In particular, inappropriate 
nutrition is an important causal element precipitating a developmental programming event that 
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may contribute to the risk of chronic disease (14). The foremost mechanistic hypothesis is that 
when a critical period of maturation is progressing under suboptimal circumstances, the 
organism adapts to ensure survival and to maintain vital functions at the expense of other less 
immediately critical functions (40). Nevertheless, the fetus’ metabolic economy mode that 
secures survival in response to prenatal adverse conditions becomes maladaptive in a postnatal 
world where nutritional resources are not limiting (40). Continued adaptations in postnatal life 
also play a role in further modulating antenatal programming.  
There are three intriguing and fascinating facets about the epigenetic state that are 
important to relate in the context of developmental programming (41). First, epigenetic states can 
be paradoxically both reversible and heritable. Second, epigenetic states can be both heritable 
across cell divisions in somatic cells and potentially “inherited” across several generations. 
Third, epigenetic states can be both carriers of “memory” of early life experiences and “triggers” 
of disease susceptibility in later life. Because of the reversible nature of epigenetics, it can be 
modified by many external factors, which may cause the development of an unusual phenotype 
(42). Standard physiological responses to these different stimuli also may be changed by 
epigenetic mechanisms (42). The Developmental Origin of Health and Disease (DOHaD) 
hypothesis proposes that some disorders, such as type 2 diabetes mellitus and cardiovascular 
disease, can result from an imbalance between the environments that are experienced in utero, in 
early infancy, and later in life (43). The key feature of the “epigenotype model” of DOHaD is 
largely based on the finding that the environment can modulate epigenetic states. Indeed, there is 
mounting evidence that links environmental stimuli and the epigenome. Examples include 
behavioral programming by maternal care in rats, and divergence between genetically identical 
inbred mice (44, 45). Furthermore, environmental influences in early life can induce permanent 
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alterations in the epigenotype and determine adult phenotypes and disease susceptibility. 
Epigenetic misprogramming may occur throughout development; however environmentally 
induced changes that affect programming during early development have a greater and more 
widespread effect than those that occur during less “plastic” times in development (46).  
 
1.2.3 Critical window of susceptibility 
 
Sensitive periods in fetal and postnatal developmental exist during which even minor 
interventions can have long lasting effects on adult physiology (47). Fetal or neonatal exposure 
to chemicals is an important concern since developing organisms are tremendously susceptible to 
perturbation by chemicals. Harmful effects may happen at concentrations of the chemical that are 
far below levels considered toxic in the adult (48). Furthermore, the timing of exposure is 
important as developing systems show critical periods of susceptibility to various chemicals such 
that an exposure during this critical period will lead to abnormalities in organ function, which 
may not occur when the exposure occurs at some other time of development (48). These critical 
windows of susceptibility can be explained by the fact that the protective techniques that are 
available to the adult, such as DNA repair mechanisms, a competent immune system, detoxifying 
enzymes, liver metabolism, and the blood/brain barrier as examples, are not completely 
functional in the prenatal or early postnatal period (49). Additionally, the developing organism 
has an enhanced metabolic rate as compared with an adult, which, in some cases, can result in 
increased toxicity (49). During a critical window, exposure to environmental factors will modify 
normal cellular and tissue development and function resulting in developmental programming 
and a risk for metabolic and hormonal ailments later in life. Therefore, exposures during critical 
windows of prenatal advancement usually do not manifest until much later in life (50).   
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Since each system of organs has various developmental trajectories, and the sensitive 
window for exposures to different factors varies relative to the stage of tissue development, the 
consequences of exposures depend not only on the type of exposure, but on the time when the 
exposure occurs (50). A number of studies illustrate that the in utero developmental period is a 
critically sensitive window of vulnerability (51, 52). Disturbances during the critical window of 
susceptibility can lead to subtle functional switches that may not appear until later in life. 
Mounting evidence also indicates that brief systemic inflammation during critical periods of 
development may results in long-lasting cerebral and peripheral vulnerability (programming or 
sensitization) well into adulthood (53).  
Heindel and Newbold showed several significant principles that depict how early life 
environmental vulnerabilities contribute to high risk of adult disease (54). Chemical exposures 
can have both tissue-specific and time-specific ramifications on growth and development (55). 
As long as tissue is developing, it is susceptible to disturbances from environmental 
vulnerabilities. These disturbances can result from alterations in gene expression, protein 
activity, cell communication or other mechanisms (54). The consequences of environmental 
chemical vulnerabilities can be transgenerational, therefore influencing future generations. 
 
1.2.4 L-Carnitine  
 
         1.2.4.1 General aspects of L-carnitine 
 
In early twentieth century, carnitine was first discovered in skeletal muscle extracts (56). 
Carnitine is a low molecular weight, quaternary ammonium compound and it is present in both 
Levo (L) and Dextro (D) forms. However, L-carnitine is the biologically active form. L-
Carnitine is a trimethylated amino acid that plays an important role in the transfer of long-chain 
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fatty acids (LCFAs) across the inner mitochondrial membrane. L-Carnitine is biosynthesized in 
mammals from two amino acids, L-lysine and L-methionine, and also is supplied from dietary 
sources (57). In mammals, L-carnitine is present as free L-carnitine, the major form in the total 
L-carnitine pool, and as esterified derivatives, which are the catalytic products of carnitine 
acyltransferases. The acylcarnitines appear as the result of the reaction when acyl moieties (short 
chain or long chain) are transferred to carnitine from acyl-CoA (58).  
 
1.2.5 L-Carnitine Functions 
 
L-Carnitine has a number of direct and indirect roles in many mammalian physiological 
systems and these essential functions directly or indirectly regulate overall energy metabolism 
(59). L-Carnitine plays a major role in mitochondrial β-oxidation of long-chain fatty acids by 
facilitating their transport across the inner mitochondrial membranes and is of utmost 
significance for maintaining normal mitochondrial function (3, 60, 61). It is also involved in the 
transport of peroxisomal β-oxidation products to the mitochondria, restoration of normal acyl-
CoA/CoA balance, and regulation of toxic effects of metabolites produced in fatty acid 
metabolism (61).  
Recent experiments and clinical studies have shown that mitochondrial dysfunction 
secondary to a disruption of L-carnitine homeostasis cause in decreased nitric oxide signaling 
and the advancement of endothelial dysfunction (62). L-Carnitine is transported via the 
circulation and is then taken up by other tissues through active transport systems. In the kidney, 
L-carnitine and butyrobetaine are reabsorbed efficiently to minimize urinary loss. Sodium-
dependent cationic transporter (OCTN2) is the primary known transporter responsible for both 
the active transport of L-carnitine to other tissues and reabsorption in kidney (63, 64). 
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1.2.5.1 Long-chain fatty acid oxidation 
 
The mitochondrial β-oxidation of long-chain fatty acids is the cardinal energy producing 
process for organs that require long-term energy. Long-chain fatty acids cannot cross the inner 
mitochondrial membranes for further metabolism due to structural limitations. Palmitoyl-CoA 
synthetase (PCS) is the first enzyme in the fatty acid transport process (65). PCS is located in the 
outer mitochondrial membrane and activates fatty acids that are present in the cytosol to produce 
coenzyme A-derivatives (acyl-CoA) of fatty acids. Carnitine palmitoyltransferase I (CPT I) 
located in the outer mitochondrial membrane facilitates the transesterification of acyl-CoA and 
produces acylcarnitines (66, 67). In transesterification, the acyl moiety of the long-chain fatty 
acids is transferred from CoA to the hydroxyl group of carnitine. Specific transporters mediate 
the transport of the long chain fatty acids into mitochondrial matrix such as carnitine-
acylcarnitine translocase (CACT), which exchanges one long-chain acylcarnitine for one 
carnitine. Carnitine palmitoyltransferase II (CPT II) facilitates the back conversion of 
acylcarnitine to carnitine and the particular long-chain acyl-CoA. Within the mitochondrial 
matrix acyl-CoAs undergo β-oxidation and enter the respiratory chain. L-Carnitine is 
subsequently translocated by translocase or modified to acylcarnitines in the matrix of 
mitochondria. Carnitine acyltransferases transfer the acyl group from acyl-CoA to L-carnitine. 
These enzymes can be divided into three types (58) : 1) carnitine palmitoyl transferase (CPT), 
which transfers medium and long-chain acyl-CoA with more than 12 acyl groups to L-carnitine 
with a preference for long-chain acyl-CoA, at least at physiological concentrations of L-
carnitine; 2) carnitine octanoyltransferase (COT), which uses both medium and long-chain fatty 
acids with 5-12 acyl groups having a preference for medium-chain acyl-CoA; and 3) carnitine 
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acetyltransferase (CrAT), on the basis of their specification to acyl groups and their cellular 
settling employs short-chain acyl groups (C1–C4) as substrate. The CPT system is a significant 
feature of the carnitine shuttle, which facilitates the transfer of long-chain fatty acids from 
cytosol into the mitochondrial matrix, the site of β-oxidation.  
The CPT system includes carnitine palmitoyltransferase 1 (CPT-1) localized in the outer 
mitochondrial membrane, the carnitine–acylcarnitine translocase (CACT), an integral inner 
membrane protein, and carnitine palmitoyltransferase 2 (CPT-2) localized on the inner 
mitochondrial membrane (68). CPT-1 conjugates L-carnitine with LCFAs, CACT transfers the 
acylcarnitine across the inner plasma membrane, and CPT-2 conjugates the fatty acid back to 
coenzyme A for subsequent β-oxidation. CPT-1 has various isoforms with tissue-specific 
expression, CPT-1A (liver), CP T-1B (muscle) and CPT-1C (brain) (69). Finally, CrAT, which is 
situated in the mitochondrial matrix, has the ability to reconvert the short and medium chain 
acyl-CoAs into acylcarnitines using intramitochondrial carnitine. Decreased CrAT activity 
results in increased levels of acyl-CoA, which causes in inhibition of many enzymatic processes 
involved in oxidative metabolism (70) (71-73).  
 
1.2.5.2 Regulating the mitochondrial acyl-CoA/CoA ratio and toxic effects 
 
In the process of long chain fatty acid transport, carnitine acyletransferase produces 
acylcarnitines and free coenzyme A (CoA) in the inner mitochondrial matrix. L-Carnitine acts as 
a buffer for free CoA (74). Through the action of CAT, L-carnitine and CoA pools are in close 
relationship. This reversible exchange allows the cell to regulate its levels of free CoA using L-
carnitine as a buffer, and since L-carnitine is present in most tissues at a much higher 
concentration than CoA, the extra mitochondrial acetylcarnitine/carnitine ratio will prevent 
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significant fluctuations in the mitochondrial acetyl-CoA/CoA ratio by formation of acyl-CoA 
(75, 76). L-Carnitine prevents the toxic effects of acyl groups, which are produced by poor 
metabolism of fatty acid oxidation, by converting those acyl groups into carnitine esters. Since 
L-carnitine exists as either free L-carnitine (nonesterified molecule; FC), or acylcarnitines 
(esterified form; AC), the AC/FC ratio is an important criterion for assessment of a functional L-
carnitine shortage (76). Enzymatic alterations in L-carnitine metabolism can result in higher 
levels of acylated carnitines and, hence, an elevated AC/FC ratio (76, 77).  
L-Carnitine mediated transport of LCFAs has 3 other distinct functions. A free CoA pool, 
both in the cytosol and within the mitochondrial membrane, is necessary for many metabolic 
processes and pathways, including the citric acid cycle, ketogenesis, and gluconeogenesis. When 
the acyl group of acyl CoA combines with carnitine, acylcarnitine esters are formed which can 
then be removed from the mitochondrial membrane and cell and thereby eliminated by liver or 
kidney. This transport of acylcarnitine esters out of the mitochondria serves 2 purposes. First, it 
maintains a pool of free CoA at the mitochondrial membrane, and second, it protects cells 
against high, and potentially toxic, concentrations of acyl CoA compounds that could inhibit 
enzyme activity in metabolic processes, thereby ultimately altering cellular ATP production (60). 
The interruptions in mitochondrial function have been identified as the main cause of 
several pathological conditions diabetes (58). L-Carnitine also removes the acyl groups from 
mitochondria as acylcarnitines. The increase in free fatty acid levels can induce mitochondrial 
dysfunction resulting in cell death and/or enhanced secondary generation of reactive oxygen 
species (ROS) (78). These effects can be attenuated with L-carnitine treatment. Studies have also 
shown that L-carnitine has a protective effect both on mitochondria and in whole cells by 
inhibiting free fatty acid induced mitochondrial membrane damage and/or its secondary effects 
13 
 
(79). The protective effects of L-carnitine and related metabolites have been postulated to be due 
to improved energy metabolism and the inhibition of electron leakage from mitochondrial 
electron transport systems. 
 
1.2.5.3 L-Carnitine Importance and Systemic Deficiency 
 
L-Carnitine deficiency was first described as a new syndrome in humans in 1973 (80). 
Until now, two types of L-carnitine deficiency have been observed: primary and secondary L-
carnitine deficiencies (81). These are commonly classified by the etiopathogenesis and organ 
involvement. Primary L-carnitine deficiency is caused by disturbances in the L-carnitine system 
itself and leads to impaired fatty acid oxidation. Primary L-carnitine deficiency is an autosomal 
recessive disorder of fatty acid oxidation, which can be associated with a novel mutation in 
SLC22A5, the gene encoding Sodium-dependent cationic transporter OCTN2 (81, 82, 83). 
Patients with primary L-carnitine deficiency have increased renal excretion of L-carnitine, and 
patients experience recurrent hypoketotic hypoglycemia and/or dilated cardiomyopathy.  
Secondary L-carnitine deficiencies are associated with an impaired mitochondrial 
oxidation of acyl-CoA intermediates, a limited supply of substrates for L-carnitine biosynthesis, 
or a dietary insufficiency (84). Secondary L-carnitine deficiency is characterized by free plasma 
L-carnitine concentrations less than 20 μmole/L or 0.39 mg/dL.  Toxicity caused by L-carnitine 
deficiency results from the accumulation of fatty acids or decreased energy production (85, 86). 
Impairment in mitochondrial fatty acid oxidation can lead to severe hypoglycemia and dilated 
cardiomyopathy. In addition, patients with inborn errors of long chain fatty acid oxidation 
present with a variety of severe clinical problems, such as cardiomyopathy, retinopathy, and 
peripheral neuropathy, presumably due to the accumulation of toxic long chain acyl CoA esters. 
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Symptoms related to a defect in OCTN2 may include fatty liver, growth retardation, 
hypoglycemia, and hyperammonemia (87). Many individuals with L-carnitine deficiency are 
generally normal at birth and may appear healthy for several years until overt clinical signs 
appear. Early identification of L-carnitine deficiency can be lifesaving because L-carnitine 
supplementation during the early stage of a L-carnitine deficiency can reverse certain 
pathological changes associated with cardiac, neural, and hepatic systems (87). 
 
1.2.6 L-Carnitine Homeostasis 
 
            1.2.6.1 De novo biosynthesis 
 
Human L-carnitine may derive from dietary sources or biosynthesis employing lysine and 
methionine. The main dietary sources of L-carnitine are red meat, fish and dairy products, which 
can provide 2–12 mmol per day per kg of body weight and 1–2 mmol of carnitine is 
endogenously synthesized (58). The kidney, liver, and brain are the main sites of L-carnitine 
synthesis. After synthesis, L-carnitine is transported via the circulation and is then taken up by 
other tissues through carrier-mediated transport systems. In the kidney, L-carnitine and 
butyrobetaine are reabsorbed efficiently to minimize urinary loss (63).  OCTN2 is the primary 
known active transporter responsible for both the transport of L-carnitine to other tissues and re-
absorption in kidney (63).   
Endogenous biosynthesis of L-carnitine involves a number of enzymatic steps (Figure 
1.1) (88, 89); however, this pathway consists of the rate-limiting enzymes, i.e  N’trimethyllysine 
dioxygenase (TMLD) and beta-butyrobetaine dioxygenase (BBH). TMLD mediates the 
hydroxylation of trimethyllysine (TML) to 3-hydroxy trimethyllysine (HTML) in mitochondria 
of liver, kidney, heart, muscle, and brain. TMLD is a non-haem ferrous-iron dioxygenase 
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requiring 2-oxoglutarate, Fe+ 2and molecular oxygen as supporting factors (90). Limited 
information is available on HTML aldolase (HTMLA) that catalyzes the aldolytic cleavage of 
HTML into 4-trimethylaminobutyraldehyde (TMABA) and glycine. TMABA dehydrogenase 
(TMABA-DH) requires NAD+ as a cofactor and liver and kidney express the highest level of 
TMABA-DH, which is low in brain, heart and muscle (90). BBH’s function is to catalyse the 
stereospecific hydroxylation of butyrobetaine to L-carnitine. BBH requires molecular oxygen, 
Fe+2 and ascorbate for activity. BBH is localized in the cytosol of mammalian cells and is 
primarily expressed in the liver, kidney, brain, testis, and epididymis (91).  
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Figure 1.1 De novo synthesis of L-carnitine.  
 
1.2.6.2 L-Carnitine absorption 
 
Dietary L-carnitine intake by humans ranges from less than 1 up to 15 μmol/kg body 
wt/day. Vegans typically acquire very little L-carnitine from diet, usually less than 1 μmol/kg 
body wt/ day. Individuals consuming dairy products obtain 1 to 8 μmol L-carnitine/kg body 
wt/day and 6 to 15 µmol L-carnitine/kg body wt/day for individuals that consume red meat (92) 
(93). The bioavailability of dietary L-carnitine ranges from 54–86% of dietary intake. In vivo and 
in vitro studies on L-carnitine uptake in the intestine reported two absorption modes, linear 
absorption and nonlinear absorption (92). Linear absorption of L-carnitine represents the 
unsaturable passive diffusion of L-carnitine across the intestinal epithelium, whereas nonlinear 
absorption represents the carrier mediated saturable and active uptake process by transporters. 
Studies of L-carnitine absorption and its components in humans, experimental animals, and cell 
culture models suggest that L-carnitine is transported from the intestinal lumen into the 
enterocyte by carrier-mediated processes, but passes across the serosal membrane into the 
circulation by simple diffusion (94). Consequently, L-carnitine is rapidly taken up from the 
gastrointestinal lumen, but is slowly released into the portal circulation. Studies with Caco-2 
polarized epithelial cell cultures and human muscle biopsy specimens suggest high-affinity, 
saturable, sodium-gradient-driven uptake of carnitine (95). Extensive intracellular acetylation of 
L-carnitine (50–60%) occurs in rat and guinea pig intestine and in isolated guinea pig 
Carnitine 
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enterocytes. In rat and guinea pig intestine, acetyl-L-carnitine is more readily released across the 
serosal membrane than is nonesterified L-carnitine (96). Intracellular acetylation of L-carnitine 
may facilitate its diffusion across the serosal membrane. In guinea pig intestine, luminal acetyl-
L-carnitine was taken up by intestinal mucosa at about the same rate as was nonesterified L-
carnitine, but the calculated efflux of total L-carnitine into the circulation was 4-fold greater for 
acetyl-L-carnitine compared to nonesterified L-carnitine (92, 97).  
 
1.2.6.3 Tissue Distribution and Renal Elimination 
 
L-Carnitine is distributed in various parts of the body with extensive distribution into 
skeletal muscle and heart. There are three distinctive pools in L-carnitine distribution in the 
human body (88). The principal pool represents muscle tissues and averages 95% of total body 
L-carnitine. The second pool consists of liver and kidneys and corresponds to total of 4% of total 
body L-carnitine. The small pool corresponds to extracellular fluids and it accounts for the 
remaining 1% of total body L-carnitine (88). The concentration in tissues such as muscle is 25-
50 fold higher than in plasma levels due principally to the activity of OCTN2 transporter that 
actively takes up L-carnitine from blood into tissues against a concentration gradient (63).  
The kidneys have a crucial and definitive role in the maintenance of L-carnitine 
homeostasis in mammals by minimizing the renal loss of L-carnitine. L-Carnitine is eliminated 
from the body primarily by renal excretion of nonesterified carnitine and acylcarnitine esters 
(63). As a small, water-soluble non protein-bound compound, L-carnitine is readily filtered by 
the renal glomerulus. The Na+ dependent active reabsorption of L-carnitine by OCTN2 occurs in 
the proximal renal tubule and helps to prevent the renal clearance of L-carnitine. The total renal 
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elimination of L-carnitine per day is estimated at approximately 100-300 μmol, which is 2-10% 
of total filtered L-carnitine (92, 98).  
L-Carnitine reabsorption and excretion rates are affected by diet and physiological and 
pathological factors (99, 100). Less efficient reabsorption of acylcarnitines and renal acylation of 
L-carnitine followed by leakage of the locally formed acylcarnitine products into urine can lead 
to the high acylcarnitine to carnitine ratio in urine compared to that of plasma (99, 100). The 
efficiency of carnitine reabsorption increases as dietary intake of L-carnitine decreases, 
independent of glomerular filtration rate and filtered load (98). This adaptive response serves to 
maintain circulating L-carnitine concentration in the face of decreased input from dietary intake. 
Conversely, the rate of L-carnitine excretion increases rapidly, and the efficiency of L-carnitine 
reabsorption decreases as the filtered load of L-carnitine increases above normal, as for example 
following ingestion of a dietary L-carnitine supplement or by intravenous infusion of L-carnitine 
(98).  A “threshold” effect is observed at near-normal plasma L-carnitine concentrations, above 
which the rate of L-carnitine excretion soon parallels the increase of filtered load. This 
homeostatic mechanism serves to maintain circulating L-carnitine concentrations in a narrow 
“normal” range (98).  
L-Carnitine is required as a cofactor in the transport of long-chain acyl groups (fatty acids) 
across the mitochondrial membranes to facilitate the β-oxidation of LCFA and hence ATP 
production. L-Carnitine uptake into tissues is mediated through different transporters; 1) organic 
cation/carnitine transporters (OCTNs), 2) neutral and cationic amino acid transporter, ATB0,+, 
and 3) carnitine transporter 2 (CT2). Polyspecific organic cation transporters belong to the 
SLC22 family and the MATE family (101). The SLC22 family contains the three subtypes of 
passive diffusion organic cation transporters called OCT1 (SLC22A1), OCT2 (SLC22A2) and 
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OCT3 (SLC22A3); Organic cation/carnitine transporter OCTN1 (SLC22A4) that may be a 
proton cation exchanger; the Na+-carnitine cotransporter OCTN2 (SLC22A5), which facilitates 
the Na+ independent transport for organic cations and L-carnitine; and organic cation transporter 
OCT6 (SLC22A16) (101). 
Apart from OCTNs, ATB0,+ also transports L-carnitine across cellular membranes. This 
transporter belongs to the SLC6A family of transporters (102). The letter B of ATB0,+ represents 
broad substrate specificity of the transporter system and the superscript represents both neutral 
and cationic amino acids as substrates to this transporter (102). ATB0,+  transports amino acids 
depending on Na+ and Cl- ion concentrations across the cell membrane. ATB0,+ has low affinity 
for L-carnitine and is expressed in the lung, colon, mammary gland, pituitary gland and ocular 
tissue (103-105). Furthermore, L-carnitine is transported by L-carnitine transporter 2 (CT2). This 
novel transporter belongs to the SLC6A family of transporters and is expressed in human testis. 
The localization of these transporters in tissues and at epithelial barriers is critical in 
understanding their endogenous role in cellular metabolism and function. For example, 
expression of OCTN3 in peroxisomal membranes plays a critical role in peroxisomal β-oxidation 
pathways (106). 
 
1.2.6.3.1 Organic Cation/Carnitine Transporters  
 
Organic Cation/Carnitine Transporters (OCTNs) are members of the Solute Carrier 
Transporter 22 (SLC22) family (107, 108). Although SLC22 members can transport cationic 
chemicals, OCTNs are most notably known for their ability to mediate the cellular uptake of L-
carnitine (107). OCTN class has three different transporters, OCTN1, OCTN2 and OCTN3. 
OCTN1 was first cloned from a human liver cDNA library, and rodent rat and mouse isoforms 
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were later isolated (109). OCTN1 transporter protein consisted of 11 transmembrane domains 
and one-nucleotide binding domain. OCTN1 is a sodium-independent organic cation transporter 
that transports cations in a bidirectional, pH dependent manner. It is a multispecific transporter 
and has low affinity for L-carnitine in species including rat and humans. It is abundantly 
expressed in intestine, liver, and kidney (110, 111).  
OCTN2 was cloned from a human kidney cDNA library and OCTN2 possibly has 12 
transmembrane domains (112). OCTN2 has high affinity for L-carnitine and transports L-
carnitine in a sodium-dependent manner. The unique aspect of this transporter is its dual mode of 
transport: it transports organic cations via a sodium independent process and L-carnitine via a 
sodium dependent process (113). It is widely expressed in tissues such as heart, skeletal muscle, 
kidney, intestine, placenta, brain and mammary gland. A mutation in the OCTN2 gene causes 
secondary L-carnitine deficiency (114). OCTN1 and OCTN2 transporters show more than 70% 
similarity in their amino acid sequence; however, it is identified that both transporters 
demonstrate differences in their function (115). OCTN3 was first detected in mouse kidney, and 
OCTN3 protein has later been detected in a human cell line (116). OCTN3 transports L-carnitine 
in a passive, sodium and pH independent manner. It has higher specificity for L-carnitine 
transport than OCTN1 and OCTN2. It is predominantly expressed in testis and in peroxisomes 
(117).  
 
1.2.6.3.2 OCTN2 (Slc22A5) transport 
 
OCTN2 has a relatively ubiquitous distribution and is expressed in epithelial cells, muscle 
cells, glial cells, macrophages, lymphocytes and sperm. In humans, the strongest expression of 
OCTN2 was found in liver (118), kidney (119) (120), skeletal muscle (121), heart, placenta, 
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brain (122), mammary glands (123), and blood-retinal barrier (124). As well OCTN2 is 
expressed in intestinal tissues (125) and contributes to the absorption of L-carnitine. In heart, 
OCTN2 protein is present in the vascular endothelium (124). OCTN2 transporter expression was 
also found in some cancer cell lines suggesting that L-carnitine has a crucial role in maintaining 
energy metabolism in cancer cells. In rodents, Octn2 was wider distribution than in human (126). 
Octn2 was found in blood vessels, and astrocytes. In kidney of rat Octn2 transporter is localized 
to the apical membrane of proximal tubular epithelial cells (126). In mice, octn2 has localized to 
the apical membrane of cells lining the epididymal ductules and of proximal tubular epithelium 
in kidney (126).   
Sodium-dependent, high-affinity carnitine transporter, OCTN2, is responsible for the active 
transport of L-carnitine into several tissues (Figure 2). Skeletal muscle and cardiac muscle utilize 
fatty acids as an energy source; therefore, a deficiency of L-carnitine in these tissues leads to 
cardiomyopathy and muscle weakness. In juvenile visceral steatosis (jvs) mice, which exhibit a 
Secondary Carnitine Disease (SCD) phenotype, alterations in intestinal absorption, tissue 
distribution, and elimination of L-carnitine have been observed (85, 127, 128). Pathologically, 
jvs mice display severe lipid accumulation in the liver, hypoglycaemia, hyperammonaemia, and 
growth retardation (129). It was confirmed that L-carnitine transport activity is impaired due to 
mutation of the octn2 gene in jvs mice and mutation of the OCTN2 gene in SCD patients. In 
addition, Japanese individuals and familial members who are affected by L-carnitine deficiency 
have various mutations in the OCTN2 gene, all of which are associated with a loss or decrease of 
L-carnitine transport activity (130, 131). OCTN2 is now generally accepted to be the causal gene 
of the genetic disease SCD (130, 131). 
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Figure 1.2  Schematic of the distribution and role of Octn2 in L-carnitine disposition and 
importance of L-carnitine in long-chain fatty acid oxidation. Octn2 facilitates the reabsorption of 
L-carnitine into the systemic circulation and also Octn2 mediated transport of L-carnitine from 
blood to various tissues. 
 
1.2.7 L-Carnitine Homeostasis in Neonates 
 
The shift in nutritional source from the maternal umbilical blood supply to milk causes 
important physiological changes in newborns. The source for metabolic energy for the fetus 
comes from carbohydrate sources, mainly glucose, whereas neonates rely less on carbohydrate 
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sources and more on fatty acids (132). The newborn must adapt to the shift in energy substrate 
supply. Development of fatty acid utilization mechanisms is requisite to guarantee appropriate 
physiological development. Moreover, fatty acid oxidation is the part of thermal homeostasis in 
neonates, and disorders in fatty acid oxidation predispose to a risk for sudden infant death 
syndrome (133). In neonates, L-carnitine is essential for long-chain fatty acid oxidation. Fatty 
acid oxidation rates increase in early stages of neonatal development and these results correlate 
with the evidence that show increased levels of L-carnitine concentrations in neonates (134).  
In neonates, the concentration of free L-carnitine in the plasma characterizes the balance 
between intestinal uptake, biosynthesis, and reabsorption by the kidney. The plasma L-carnitine 
concentration increases from postnatal day 8 of life and reaches adult levels at 4-7 months of age 
in human (134, 135). In early postnatal development, neonates depend on an exogenous source 
as enzymes required for L-carnitine biosynthesis are very immature. Hepatic γ-butyrobetaine 
hydroxylase (γ-BBH) levels are extremely low in early stages of life and the activity of BBH 
enzyme increases with age (136). Expression of BBH mRNA, however, was undetectable in 
foetuses and newborn rats (136). Gene expression of Bbh enzyme in rat shows an increase 
between postnatal day 4 and 20, but significant increases have been seen between postnatal day 4 
and 11. In addition to the maturation of Bbh enzyme, Cpt and trimethylamino hydroxylase 
(Tmlh) expression and enzyme activities increase during postnatal development (136).  
The kidneys play a dual role in body L-carnitine homeostasis. The kidneys efficiently 
reabsorb filtered L-carnitine via OCTN2 and, at least in humans, the kidneys are involved in L-
carnitine biosynthesis. Foetal rat kidneys express Octn2 mRNA and the same transcript is present 
in all ages studied (91). In human kidneys, however, neither BBH nor TMABA-DH activities 
were affected by age. Plasma L-carnitine concentration is maintained within a narrow range in 
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spite of the continuous supply of L-carnitine to the plasma under normal physiological 
conditions (137). Renal clearance is the determining factor in the maintenance of plasma levels 
of L-carnitine and renal clearance is largely determined by the kinetic properties of the brush-
border Na+/L-carnitine cotransporter, OCTN2. Renal reabsorption of free carnitine is 98% and 
99% of the filtered load, unless the transporters become saturated. Hence, the kidney has a dual 
role in L-carnitine homeostasis: it minimizes clearance of L-carnitine in the urine and also the 
kidney is involved in biosynthesis of L-carnitine in human (138-141). To our knowledge, limited 
data are available regarding: (i) at what stage of nephrogenesis the OCTN2 transporter is first 
apparent and at what stage its activity corresponds to that in adults, and (ii) whether renal 
expression of BBH and TMABA-DH mRNAs are affected by ontogeny. A systematic study on 
the ontogeny of Octn2, Bbh and Tmlh in foetuses, newborn, suckling, weaning and adult rats 
was conducted to develop concrete knowledge on ontogeny of L-carnitine mechanisms (136). 
The results suggest that the kidneys of rat foetuses have a functional OCTN2 transporter and that 
with development increases in the activity and mRNA expression of OCTN2 and the expression 
of BBH and TMABA-DH mRNAs is observed. 
 
1.2.7.1 Ontogeny of Bbh and Tmlh 
 
The renal expression of TMABA-DH and BBH undergoes a developmental maturation in 
human and rats (91). TMABA-DH mRNA was detected in foetuses and its abundance 
significantly increased from neonatal to adult rats. Renal BBH mRNA expression, however, was 
not detected until the suckling period and thereafter it was significantly modified by age in rats 
(91). Therefore, the kidney and liver tissue of foetuses and newborn rats cannot synthesize L-
carnitine or at least the turnover of L-carnitine during these periods is not sufficient to conduct 
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normal physiological functions. Although adult rat kidney expresses BBH and TMABA-DH 
mRNAs, this expression was much lower than that measured in liver, suggesting that in the rat at 
least, L-carnitine biosynthesis occurs mainly in the liver. In adult rat, it is reported that the 
activity and expression levels of these two enzymes in liver and kidney were increased at least by 
several fold suggesting clear ontogenic changes in L-carnitine biosynthesis maturation (91). In 
humans neither renal BBH nor TMABA-DH, activities were affected by age, whereas liver BBH 
activity and mRNA levels were increased by maturation.  
 
1.2.7.2 Ontogeny of Octn2 
 
The shift in nutritional source in neonatal diet necessitates the ontogenic changes in L-
carnitine homeostasis mechanisms. The neonatal diet has a considerably higher content of fatty 
acids originating from milk. Hence, neonates require maturation of fatty acid oxidation 
mechanisms to generate the energy from a fatty acid rich diet. Transporters, mainly OCTN2, 
involved in L-carnitine homeostasis, undergo changes in neonates to utilize the fatty acid rich 
diet during the postnatal development (126). In newborns, the uptake of exogenous L-carnitine 
from intestine in early postnatal days is necessary to maintain systemic L-carnitine levels as 
endogenous synthesis is limited. In vivo studies reported the postnatal development of key 
factors involved in L-carnitine homeostasis (136). Na+-Dependent L-carnitine uptake rate in 
intestine is significantly higher in both pre-term foetuses and newborn rats than in suckling rats. 
After weaning, Na+ dependent L-carnitine uptake is no longer measurable in any intestinal 
regions examined.  This is consistent with the peak in Octn2 expression in intestine in newborn 
rats with expression levels decreasing with age. Octn2 expression in the ileum was higher than in 
jejunum. In addition to the transporter expression data, the rate of Na+ independent L-carnitine 
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uptake also increased after birth, and thereafter it decreased during the suckling period until it 
reached adult values (91). Developmental maturation is associated with a decrease in the number 
(and/or activity) of the intestinal L-carnitine uptake carriers.  
Decreases in rat intestinal Octn2 expression with the age indicates that in rats, homeostatic 
control of serum L-carnitine concentration switches from dietary intake of L-carnitine in the 
intestine to de novo biosynthesis in liver and kidney (142) (143). During the late gestation period 
and early stage of life, the rat L-carnitine biosynthetic pathway is immature and the demand for 
L-carnitine may exceed its endogenous biosynthesis (142) (143). Foetuses and neonates would 
therefore depend upon external sources of L-carnitine to meet their metabolic needs. During 
these periods, the mother’s liver L-carnitine biosynthesis and intestinal Octn2 is up-regulated, 
and rat pups may receive most of their L-carnitine from their mother. Several studies suggested 
that foetal L-carnitine is derived from the mother via transplacental transfer of L-carnitine, which 
is supported by the observation that OCTN2 is expressed in human placenta (144). Age-
dependent changes in Octn2 transporter expression levels in rat kidney were reported previously 
in addition to the studies on intestinal Octn2 expression levels (91, 136). Foetal rat kidneys 
express Octn2 mRNA and the same transcript is present in all the ages studied. As previously 
reported, Octn2 mRNA abundance is up-regulated in kidney by maturation, mainly in the renal 
cortex (126, 145). These findings suggest that from the end of the gestation period to adulthood, 
Octn2 mediates renal Na+/L-carnitine transport and this corroborates the view that maturation 
increases the number of Octn2 transporters at the apical membrane.  
The findings of ontogenic changes of intestinal L-carnitine uptake and Octn2 transporter 
expression correlate with the maturation of L-carnitine biosynthesis mechanisms.  In the early 
stage of life, when the demand for systemic L-carnitine exceeds the endogenous capacity for its 
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biosynthesis, rat pups receive most of their L-carnitine from exogenous sources by active uptake 
by OCTN2 transporters. In the growing rat, however, the endogenous capacity for L-carnitine 
synthesis is increased sufficiently, and its intestinal Na+/L-carnitine transport activity is no 
longer measurable. Therefore, in the same individual, up-regulation of the liver L-carnitine 
biosynthesis is accompanied by the down-regulation of its intestinal Na+/L-carnitine transport 
activity (143, 146). In isolated brush-border membrane vesicles (BBMV), OCTN2 transporter 
expression was increased significantly in the postnatal stage. Between the postnatal day 5 and 11, 
heart, renal and intestinal OCTN2 mRNA levels showed significant changes and the expression 
increased to 80% of its adult levels (126). The observed changes in activity of transporters and 
enzymes involved in L-carnitine biosynthesis demonstrate the significant maturation of L-
carnitine hemostasis in neonates during the postnatal day 1 and 20. In addition, evidence 
suggests the ontogeny of transporters and enzymes can be modified by various effects, even 
though expression is genetically programmed (147). Furthermore, intestinal membrane lipid 
composition, fluidity and activity of Na+-dependent D-glucose transport are affected by dietary 
fat. It is inferred that the modifications in normal neonatal health during neonatal development 
may influence the ontogeny of transporters and enzymes.  
 
1.2.8 Inflammation and its effect on transporter expression and function 
 
The immune system is primarily responsible for the control or eradication of 
pathophysiological conditions that are established in mammalian system by a disease-causing 
organism or by processes that elicit an inflammatory response (148). The response of the 
immune system to pathogenic and pathophysiological conditions is activation of a series of 
events denoted as the inflammatory/immune response. The inflammatory response is coordinated 
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by an array of diverse mediators originating from diverse cell types. There is a large body of 
evidence in pharmacology suggesting that changes associated with the inflammatory response 
are responsible for significant changes in drug disposition (149). 
A considerable amount of attention has been given to the effect of inflammation on drug 
disposition mechanisms in recent years (150).  In the adult, effects of inflammation on 
transporters involved in uptake and disposition of various nutrients, mainly L-carnitine and drugs 
have been investigated (151, 152). In recent studies, it is reported that administration of 
endotoxin significantly decreased bile flow due to the effect of an inflammation-mediated down-
regulation of hepatic organic anion and renal glucose transporters (153, 154). As well, interferon-
γ (IFN- γ), a principle cytokine, is responsible for induction of the inflammatory response by 
increased expression of the di/tri-peptide transporter h-PEPT1 (SLC15A1) in cultured human 
intestinal cells (Caco-2) (155, 156). Pro-inflammatory cytokines, Tissue Necrosis Factor-Alpha 
(TNF)-alpha, Interklukin-6 (IL-6) and Interlukin-1 β (IL-1 β), decrease solute carrier (SLC) and 
multi drug resistant transporter (MRP) expression in primary human hepatocytes (157, 158). The 
expression profile of OCT1 (SLC22A1) is of particular interest because of its close relationship 
to OCTN family transporters (159, 160). OCT1 expression was decreased several fold when 
hepatocytes were exposed to IL-6 and IL-1β. It is reported that one of the major components 
responsible for developing the inflammatory response, TNF-α, induced a sustained decrease in 
Ntcp, Oatp1/Oatp1a1, and Bsep mRNA expression as well as a transient effect on expression of 
multidrug resistance associated protein 2 (Mrp2) (161). Studies reported that the decrease in 
mRNA expression of Octn2 transporter in rat colon is a significant factor for development of 
inflammatory bowel disease (162). Many transporters have been shown to be down regulated 
with LPS administration and in inflammatory diseases. Moreover, the effects of inflammation on 
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various drug transporters and the pharmacokinetic consequences of altered drug transporter 
expression have undergone some investigation (163).  
The identification of the complex relationship between inflammation and regulation of 
transporter expression is in its initial stages. However, evidence suggests the involvement of 
class II nuclear hormone receptors in transcriptional regulation in inflammatory conditions (164, 
165). The effects of endotoxin treatment on transporter expression and the activity of 
corresponding transcription factors have been studied in detail (166, 167). Endotoxin treatment 
leads to down regulation of sodium dependent taurocholate cotransporter Ntcp (Slc10a1) protein 
expression, mRNA levels, transcription initiation, and reduces nuclear levels of its key 
transactivators, hepatocyte nuclear factor 1 (HNF-1; TCF1) and the nuclear receptor heterodimer 
retinoid X receptor:retinoic acid receptor  (RXR:RAR) (168, 169). The mechanism of pro-
inflammatory cytokine-regulated regulation of transporter expression has been clearly 
investigated (170, 171).  However, the ability of the inflammatory stimulus to alter the ontogeny 
of enzymes and transporters involved in nutrient homeostasis in neonates has not received much 
attention. 
 
1.3. Rationale and Purpose: 
 
An important and yet to be answered question is the potential external factors that are 
likely to affect developmental programming of L-carnitine homeostasis. Many approaches are 
used to understand those factors involved in epigenetic regulation, but few studies evaluate 
importance of nutrition and macro- or micronutrients. Previous work in my laboratory assessed 
the impact of a drug on L-carnitine homeostasis pathways to provide perspective on the impact 
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of exogenous factors on the maturation of L-carnitine homeostasis processes and the possible 
long-term results of a drug exposure on the maturing physiological system.  
At present, very little information exists on the impact of disease on normal developmental 
programming. Inflammation is a common condition of neonatal disease and the adult literature 
clearly indicates that inflammation alters expression of various nutrient and xenobiotic 
transporters and enzymes. The purpose of this thesis is to resolve an important question, whether 
an inflammatory stimulus in neonates can cause significant changes in the ontogeny of L-
carnitine homeostasis and change the maturing physiological processes involved in L-carnitine 
homeostasis.  Regardless of the fact that we know much about L-carnitine homeostasis and 
biosynthesis and its physiological importance, we have much to learn about the mechanisms and 
regulatory signals of ontogeny of L-carnitine homeostasis mechanisms. Information about how 
factors associated with ontogeny change relative to each other under inflammatory conditions 
will offer an improved understanding of the processes involved in L-carnitine homeostasis and 
physiological maturation of organs crucially associated with fatty acid metabolism. The 
information which will be gathered from this research will have clinical significance.  
 
4. Hypothesis and Objectives  
 
At present, there is very little information on the potential ability of inflammation in 
neonates to cause alterations in the normal ontogeny of L-carnitine homeostasis mechanisms. 
The effect of inflammatory stimuli in neonates could differ depending on age, intensity of 
exposure, and the timing of that exposure during neonatal development. Such inflammatory 
stimulus effects may lead to adaptive approaches that alter the normal ontogenic pattern of L-
carnitine homeostasis in neonates. The overarching hypothesis of this thesis is as follows:  
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Hypothesis: An inflammatory stimulus will alter the ontogeny of L-carnitine homeostasis 
pathways and this depends upon when the inflammatory stimulus occurs in postnatal 
development. 
Objectives 
 
i. Evaluation of the effect of inflammation on Octn2 transporter expression in different 
age groups of neonates. 
ii. Evaluation of effect of inflammation on ontogeny and activity of enzymes involved in 
carnitine biosynthesis and whether this differs depending upon when in postnatal 
development the inflammatory stimulus occurs. 
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Chapter 2 
2. Materials and Methods 
 
2.1 Animals:  
 
Female Sprague-Dawley (SD) rats ordered at gestation day 14 (for pups at postnatal day 3, 
7 and 14) (n=4 of each postnatal stage) were obtained from Charles River Canada (St. Constant, 
PQ) and were housed singly in a room temperature and humidity controlled facility (22°C ± 2°C) 
on a 12-hour light:dark cycle (0700 h – 1900 h). All rats had free access to food (Prolab® RMH 
3000, Purina, Inc., Richmond, IN) and water throughout the study and were allowed a 7-day 
acclimatization period. All animal experimental procedures were approved by the University of 
Saskatchewan’s Animal Research Ethics Board, and adhered to the Canadian Council on Animal 
Care guidelines for humane and animal use. A MilliQ Synthesis (Millipore, Bedford, MA) water 
purification system provided purified deionized water. 
2.2 Materials 
 
Sterile 15 mL and 50 mL polypropylene centrifuge tubes, 12 well plates, 96 well plates, 
eppendorf tubes, bicinchoninic acid (BCA) protein assay kit, and 4 mL scintillation vials were 
purchased from Thermo Fisher Scientific (Ottawa, Ontario, Canada). Quantitative reverse 
transcription-polymerase chain reaction (QRT-PCR) tubes and two-step SYBR green RT-PCR 
kits were acquired from Applied Biosystems (Foster City, California, USA). Ribonucleic acid 
(RNA) isolation mini kit and reverse transcription kit were purchased from Qiagen Inc. (Toronto, 
Ontario, Canada). Enzyme-Linked Immuno Sorbent Assay (ELISA) kits for tumour necrosis 
factor alpha were purchased from Sigma-Aldrich (Toronto, Ontario, Canada). Adenosine 
triphosphate (ATP), adenosine diphosphate (ADP), adenosine monophosphate (AMP), creatine 
(Cr), creatine phosphate (CrP), L-carnitine, horse serum, trypsin, phosphate buffered saline, and 
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lipopolysaccharide (LPS: Escherichia coli strain O55:B5) were purchased from Sigma-Aldrich 
(Toronto, Ontario, Canada). High performance liquid chromatography (HPLC) grade methanol 
was purchased from Fisher Laboratories (Toronto, Ontario, CA). Highly purified deionized water 
was obtained from a MilliQ Synthesis water purification system (Millipore, Bedford, MA). All 
other solvents and reagents used were of the highest analytical grade available. 
2.3 Acute LPS Administration in Rat Pups 
 
Pregnant SD rats (14 days gestation) were obtained from Charles River and housed in pairs 
according to usual animal husbandry procedures. Two days prior to expected parturition, dams 
were housed individually. Pups culled from litters were humanely killed by isoflurane 
anaesthesia and exanguination by cardiac puncture. At postnatal day 3, 7 and 14, pups were 
removed from their dams for short duration (maximum 15 minutes). During this time body 
weight was measured. For each litter, half of the pups were randomly selected to receive an 
intraperitoneal injection (0.1 mL) of LPS and the other half saline (0.1 mL). LPS was 
administered at 0.1 mg/Kg bodyweight in 1 mL/Kg pyrogen-free saline. This dose (0.1 mg/Kg 
LPS) was reported in the literature to cause a febrile reaction in neonatal rat pups but not death 
due to endotoxaemia (172). The litter is considered an individual sample and four litters were 
used per postnatal treatment day (to give a sample size of n=4/group) and male/female pups from 
a single litter are considered a replicate within that individual sample.  
At 3 and 16 hours post-LPS administration, pups were humanely killed following 
isoflurane anesthesia and blood, heart, intestine, kidney and liver rapidly collected. The dosing 
schedules were considered from results obtained from careful review of literature (173) and from 
a pilot study to monitor short-term and long-term inflammatory effects and developmental 
maturation of L-carnitine biosynthesis pathways in rat pups (postnatal day 3, 7 and 14). Blood 
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samples were collected in glass tubes and left for 1 hour at 37°C to allow them to clot. The 
serum was separated from blood by centrifugation at 1700 x g for 20 minutes @ 4°C, and 
transferred to new eppendorf tubes with storage at -20°C. All tissues were snap frozen in liquid 
nitrogen and stored at -80ºC. Blood and tissues were pooled from 3-4 pups from a single dam at 
each time points such that the dam was considered the experimental unit. 
2.4 Serum Tumour Necrosis Factor – Alpha (TNF-α) Levels 
 
TNF-α activity in serum was measured using enzyme-linked immunosorbent assay 
(ELISA). Quantitative analysis of TNF-α was performed for pooled serum samples according to 
the manufacturer’s protocol. In brief, specific antibodies for rat TNF-α was coated on 96-well 
plate well. In the first step, standard samples were added to wells to develop a standard curve to 
calculate the TNF-α levels in samples. Standard samples were washed four times with wash 
buffer and then biotinylated anti-rat TNF-α antibody was added. The washing step was repeated 
to wash biotinylated anti-rat TNF-α antibodies, after washing away unbound biotinylated 
antibody, HRP-conjugated streptavidin was pipetted into the wells. A 3,3',5,5'-
tetramethylbenzidine (TMB) substrate solution was added to the wells and after one more 
washing step was employed, the color develops in proportion to the amount of TNF-α bound.  
The Stop Solution (0.2M Sulphuric acid) changes the color from blue to yellow, and the intensity 
of the color was measured at 450 nm. The same procedure was employed for serum samples. The 
slope and coefficient of determination values were found to be 0.2089 and >0.986, respectively. 
The standard curve range was linear (r2 >0.98) between 0.082-20.00 ng/mL.  
2.5 L-Carnitine Analysis in Serum and Heart 
 
Free L-carnitine present in rat serum and heart samples was measured using an HPLC-UV 
based pre column derivatization method that was previously established in our lab (136, 174). 
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The pooled heart samples were homogenized with phosphate buffer (50 mM, pH 7.4) and the 
homogenate was centrifuged (Accuspin Micro 17, Fisher Scientific) at 2500×g for 10 min at 4ºC. 
Proteins present in the heart homogenate supernatant or in serum samples were precipitated 
using acetonitrile:methanol in 9:1 v/v ratio.  For every 20 µL heart homogenate or serum, 180 µL 
of acetonitrile:methanol mixture was added. 300 mg mixture of Na2HPO4 and Ag2O (9:1 wt/wt) 
and then 300 mg of KH2PO4 was added and vortexed for 1 hour. Derivatization reagent (40 
mg/mL ρ-bromophenacyl bromide with 50 μL 40% tetrabutylammonium hydroxide solution) 
was added into the organic extract. The reaction mixture was incubated at 60ºC for 120 minutes 
in a water bath. The resulting reaction mixture was cooled immediately in cooled tap water and 
then centrifuged at 12,000×g for 15 min. Resulting final samples were filtered through micro 
filters into HPLC vials. L-Carnitine was analyzed using an Agilent 1200 HPLC system with 
Diode Array Detector (DAD), quaternary pump system and autosampler. Sample size of 10 μL 
was injected using an auto sampler onto a CN (cyano) column (HyperClone 5 μm, 250 × 4.6 
mm, Phenomenex, Torrance, CA) with detection wavelength set at 260 nm. The mobile phase 
(90% acetonitrile/10% mM citrate phosphate buffer, pH 3) was delivered at a flow rate of 1 
mL/min. Intra- and interassay accuracy and precision ranged from 0.4%- 9.6%. 
2.5.1 HPLC method validation parameters 
 
An HPLC method for free L-carnitine was validated using the standard addition method. 
The linearity of measurement was evaluated by analyzing different concentrations of the 
standard solutions of the L-carnitine hydrochloride in blank serum. The calibration curve was 
generated by subtracting peak area values obtained for standard samples from the peak area 
values of blank samples. The calibration curve was constructed by plotting average peak area 
against concentration and a regression equation was computed. The slope and coefficient of 
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determination values were found to be 12.602 and >0.99, respectively. The standard curve range 
was linear (r2 >0.99) between 1.03-66.7 μmol/L. 
2.6 Total mRNA Isolation and Quantitative RT-PCR Analysis   
 
Total RNA was extracted using RNeasy Midi Kits according to the manufacturer’s 
instructions. Frozen tissues were thawed for 15-20 min at room temperature. Cell lysate was 
homogenized with 350 μL of buffer RLT containing beta-mercaptoethanol (β-ME). To this 
homogenate, 1 volume of 70% ethanol was added to precipitate the nucleic acids. The cell lysate 
was applied to the RNeasy Midi column, and a series of buffers were added to remove the 
cellular contaminants according to the manufacturer’s instructions. The purified RNA was 
isolated from the column using a RNase-free water (30 μL). The concentration and purity of the 
isolated RNA was determined by using Nanoview spectrophotometer (GE Healthcare Life 
Sciences, Quebec, Canada). Total RNA was quantified by measuring the absorbance of a diluted 
RNA (RNA: RNase-free water) at 260 nm according to the following formula: 
Concentration of RNA = 40 μg/mL × A260 × Dilution factor 
RNA purity was assessed by measuring absorbance ratio (A260/A280) of a diluted sample of 
RNA (RNA: 10 mM TrisCl (pH-7.5)). Pure RNA has a ratio between 1.9- 2.1. All samples used 
for QRT-PCR were of high purity. Total RNA was stored at -80°C until analysis. 
2.6.1 Primer Design 
 
Gene sequences for Octn2 transporter, Tmlh, Cpt1b, Cpt2 and Bbh enzymes and β-actin 
were obtained from the National Center for Biotechnology Information Gene bank (NCBI) and 
specific primers were designed using Primer3 software (http://frodo.wi.mit.edu/) (Table 2.1). 
The primer pairs were selected using the following criteria: primer Tm (58–60°C), primer length 
(18–24 mer), limit repeats of guanosine and cytosine, and amplicon size (80–200 bp). 
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Table 2.1. Forward and reverse primer sequences, amplicon size, and predicted melt 
temperatures (Tm) for gene expression analysis of various transporters and enzymes important in 
the maintenance of L-carnitine homeostasis using QRT-PCR. 
 
Octn2: Organic cation/carnitine transporter 2; Bbh: Gamma-butyrobetaine hydroxylase; Tmlh: 
Trimethyllysine hydroxylase; CPt1b: Carnitine palmitoyltransferase 1b; Cpt2: Carnitine 
palmityolytransferase 2. 
 
Gene Accession 
number  
Forward primer  Reverse primer  Tm  
(ºC) 
Base 
pair 
β-actin  NM_001101.3  GGGAAATCGTG
CGTGCATT 
GCGGCAGTGGC
CATCTC 
86.1 76 
Octn2  NM_0006000.3  GATGGTGGAGA
AAGCCCAACGG 
GAGAGCATTTC
TGACTACACGC
AGG  
81.3 104 
Bbh NM_000576.2  ATTGAGCTGCA
TCCTCTGGT  
CATTCTGCCCC
ACCCTTCAT 
80.5 142 
Tmlh  NM_001166496  CAGCCCTCCTAC
AACTCCTG 
AGAGGTTCCTG
GACGATGTG 
81.6 190 
Cpt 1b  NM_145913.3  GGGCGTCAGAT
TTGGGGGTT 
TTGAAGATTAG
GAATGGGGAGC
G 
79.3 91 
Cpt2  NM_178498.3  GCCAGGTGAAC
CCTGCCACTTT 
GCTGGTTTGGG
GCTGGZGTGT 
83.2 145 
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2.6.2 Validation of the 2-ΔΔCT Method 
 
Primer pairs for QRT-PCR assays for Octn2 transporter, Tmlh, Cpt1b, Cpt2 and Bbh 
enzymes was initially validated to give PCR efficiency between 1.9 and 2.1 (standard curve 
using 3 serial dilutions of RNA). Serial dilutions of primer pairs (3 mM, 0.3 mM, 0.03 mM and 
0.03 M) were tested against different concentrations (2000 µg/mL, 1000 µg/mL, 500 µg/mL and 
250 µg/mL) of RNA samples. The best possible combination of primer concentration and 
template concentrations that produced the lowest Ct was selected. The PCR efficiency was 
determined from the slope of the standard curve generated with serial dilutions of cDNA 
template for each gene. It was calculated using the equation Ex = (10-1/slope) - 1, where Ex is the 
PCR efficiency. A slope of -3.32 is indicative of a PCR efficiency of 1 (100%). The PCR 
products of respective genes were verified by 2% agarose gel electrophoresis. The reactions were 
further optimized for usage of the 2-ΔΔCT method using β-actin as an endogenous standard. Only 
primers giving a PCR amplification close to 100% and the relative efficiencies between the 
target and β-actin that were approximately equal were used (i.e. the slope from log RNA 
concentration versus CT were < 0.1). Fold differences in mRNA expression between control and 
treated samples were calculated. 
QRT-PCR reactions consisted of two steps: 1) Reverse transcription (1 cycle at 48ºC for 30 
min) in order to make cDNA from RNA. 2) Real time PCR (Initial activation step (1 cycle at 
95ºC for 15 min) was followed by a three step thermal cycling (40 cycles; denaturing at 94ºC for 
15 s, annealing at 60ºC for 30 s, and extension at 60ºC for 30 s). Finally, a melt curve analysis 
from 65ºC to 95ºC at 0.5ºC/s was performed. 
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2.7 Liver γ-Butyrobetaine Hydroxylase (Bbh) Enzyme Activity 
 
γ-Butyrobetaine hydroxylase (Bbh) enzyme portion was extracted from homogenates of 
liver samples by employing two successive centrifugation steps. 100 mg of liver tissue was first 
homogenized in 100 mL of homogenization buffer (300 mM sucrose, 1 mM EGTA, and 50 mM 
Tris, pH 7.5). In the first centrifugation step, the liver homogenate was centrifuged at 13,000 ×g 
for 30 min at 4ºC. The supernatant of the first centrifugation step was transferred to new tubes 
and then centrifuged at 100,000 ×g for 1 h at 4ºC. The cytosolic fraction containing Bbh was 
then subjected to dialysis (molecular weight cutoff of 12,000 Da, D9777, Sigma, USA), and was 
placed in 5 L of dialysis buffer (75 mM KCl, 0.1mM DTT and 0.5 mM EDTA in sodium 
phosphate buffer, pH 7.4) in a glass beaker covered with parafilm for 12 hours at 4°C (175). The 
dialyzed samples (20 µL), which remains in dialysis tube, were tested for L-carnitine residue and 
the remaining dialysate was stored at -80ºC for Bbh testing (176). The optimal protein 
concentration, substrate concentration, and reaction time to give linear product formation were 
determined for each age group. For determination of Bbh activity in rat pup livers, 1 mL reaction 
buffer consisting of 0.2 mM γ-butyrobetaine, 20 mM potassium chloride, 3 mM 2-oxoglutarate, 
10 mM sodium ascorbate, 0.4 mg/mL catalase in 20 mM potassium phosphate buffer (pH 7.0) 
was prepared. The reaction was initiated by addition of 2 μL ferrous ammonium sulfate (FAS) 
(final concentration was 0.25 mM) and 20 μL enzyme into 78 μL reaction buffer and incubated 
for 25 min at 37ºC using a Boekel/Grant Orbital and Reciprocating Water Bath (Model ORS200, 
ExpotechUSA, Houston, TX). The reaction was then terminated by adding 10× volume of 
acetonitrile:methanol (9:1). The mixture was centrifuged at 13,000×g for 2 min and the 
supernatant was used for L-carnitine analysis by HPLC as described above. 
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2.8 Heart Carnitine Palmitoyltransferase (Cpt) Enzyme Activity 
 
Heart Cpt enzyme activity was measured using the spectrophotometric method previously 
established in the laboratory (177). Frozen heart tissue was homogenized in 10% (wt/v) 
homogenization buffer (20 mM HEPES, 140 mM KCl, 10 mM EDTA and 5 mM MgCl2, pH 7.4) 
supplemented with 3 mg nagarse using a Polytron homogenizer (Brinkmann Instruments, 
Rexdale, Canada). The homogenate was then centrifuged at 500×g for 10 min at 4°C. The 
supernatant was collected in new tubes and centrifuged at 9000×g for 35 min at 4°C. The pellet 
was then washed with the homogenization buffer without nagarse and centrifuged at 9000×g for 
35 min at 4°C. The pellets obtained from the above steps were resuspended in 200 µL isolation 
buffer without nagarse. Protein concentration was measured using the Advanced Protein Assay 
kit (Bio-Rad Laboratories Canada, Mississauga, ON) with bovine serum albumin as standard. 
The optimal protein concentration and reaction time to give linear product formation were 
initially determined. To determine total Cpt activity 20 μg protein was assayed in 200 μL ml 
reaction buffer containing 20 mM HEPES, 1 mM EGTA, 220 mM sucrose, 40 mM KCl, 0.1 mM 
5,5’-dithio-bis (2-nitrobenzoic acid) (DTNB), 1.3 mg/mL BSA, and 40 μM palmitoyl-CoA, pH 
7.4. The reactions were initiated by adding 1 mM L-carnitine and read at 412 nm after 5 min 
incubation at 37ºC using Synergy HT Multi- Mode Microplate Reader (Biotek instrument, USA). 
Cpt2 activity was determined using the same reaction conditions as total Cpt except 10 μL 
Cpt1 inhibitior, malonyl-CoA, was added into 200 μL of the reaction mixtures to obtain a final 
concentration of 10 μM. Cpt1 activity was calculated by subtracting the Cpt2 activity from the 
total Cpt activity. The Cpt activity was calculated as amount of CoASH released per min per mg 
protein, which is based on the 5-thio-2-nitrobenzoate formation from CoASH-DNTB reaction. 
The extinction coefficient for 5-thio-2-nitrobenzoate was 13.6 mM/cm (178, 179). 
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2.9 Heart High Energy Phosphate Substrate Determination 
 
High energy phosphate substrate levels (adenosone triphosphate (ATP), adenosine 
diphosphate (ADP), and adenosine monophosphate (AMP)) and creatine compound levels 
(creatine (Cr) and creatine phosphate (CrP)) in heart samples were measured using HPLC-UV as 
described previously by Olkowski et al (180). The 1200 series High Pressure Liquid 
Chromatography (HPLC) from Agilent Technologies (Mississauga, ON, Canada) was employed 
to carry out the following assays. The HPLC system is consisted of a series 1200 quaternary 
pump with an online degasser, autosampler and diode array detector. Processed samples (10 μL) 
were injected onto a C18 column (Pursuit XRs 5C18 250×3.0 mm) using auto sampler. The 
analytes were eluted under gradient conditions (table 5) at a flow rate of 0.7 mL/min and 
absorbance was monitored at 210 nm. The mobile phase was filtered through a 0.22 μm Nylon 
filter (Pall Scientific, Mississauga, ON) and degassed in an ultrasonic bath for 30 min prior to 
use. The column was maintained at 20°C and washed with water:methanol (50:50) after every 
use. 
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Table 2.2. Gradient assay of HPLC-UV method to measure Cr, Cr P, ATP, ADP and AMP levels 
in rat pup heart sample. 
Time 
(min)  
20 mM Phosphate 
buffer (pH-5.5) 
Methanol Water Flow rate 
(mL/min) 
0.0  100 0 0 0.7 
17.0  100 0 0 0.7 
17.5  0 95.0 5.0 0.4 
19.5  0 95.0 5.0 0.4 
20.0  0 5.0 95.0 0.4 
22.0  0 5.0 95.0 0.4 
23.0  100 0 0 0.5 
28.0  100 0 0 0.7 
 
For preparation of the standards, primary stock solutions for Cr, CrP, ATP, ADP, and AMP 
were prepared at a concentration of 1 mg/mL by dissolving in phosphate buffer (pH-5.5). From 
this stock solution, 10 μg/mL of Cr, CrP, ATP and ADP, and 20 μg/mL of AMP were prepared 
and diluted serially 2 times to get a standard curve for 6 different concentrations (10 to 0.312 
μg/mL for Cr, CrP, ATP, & ADP, and 20 to 0.625 μg/mL for AMP). High quality control 
(HQC), mid quality control (MQC) and low quality control (LQC) samples at 8, 4, and 0.5 
μg/mL for Cr, Cr P, ATP, and ADP and 16, 8, and 1.5 μg/mL for ATP were prepared using the 
stock solution independent of those concentrations used for the standard curve. Primary stock 
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solutions were stored at -20°C. The standard curve range was linear (r2 >0.99). Intra- and 
interday accuracy and precision was within 12%. 
For preparation of the samples, 100 mg of heart samples were homogenized in 1 mL 0.7 M 
ice cold perchloric acid (MW 100.46) with a final concentration 100 mg/mL. The homogenate 
was centrifuged at 12,000 rpm for 5 minutes. The supernatant was collected and neutralized with 
2M potassium hydroxide to bring pH near to 7.0. The supernatant was then filtered through 0.45 
μm filter (Nonsterile Syringe Filter Nylon, Chromatographic Specialties Inc. Brockville, Ontario, 
Canada) and 10 μL was injected onto a 3μ Luna C-18 (Phenomenex, Torrance, CA) column 
using gradient flow conditions. Two mobile phase components used included 20 mM potassium 
phosphate buffer (pH 7.0) and 100% methanol. The gradient was 100% phosphate buffer from 
0–6.5 min, 100% methanol from 6.5–12.5 min, and 100% phosphate buffer from 12.5 to 25 min 
for column re-equilibration, which was sufficient to achieve stable baseline conditions. The high 
energy phosphate substrates including CrP, Cr, ATP, ADP, and AMP were monitored at 210 nm.  
2.10 Statistical Analysis: 
 
The data received from different analysis were reported as mean ± standard error of the 
mean (SEM). Comparisons for all the parameters at different ages (Postnatal Days) and time 
points (treatment time)  were analyzed using two-way ANOVA with Bonferroni post-test. The 
effects of LPS on rat pups in each treatment duration period were analyzed by two-way 
ANOVA. Data used for this purpose include serum L-carnitine levels, mRNA expression level of 
Octn2, Tmlh mRNA expression, and Bbh mRNA expression and activity in control rats from 
postnatal day (PD) 3, 7, and 14.  
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Chapter 3 
 
 
3. Results 
 
To determine whether acute inflammatory stimuli can change the normal ontogeny of L-
carnitine homeostasis in neonates, rat pups at different age (PD3, 7 and 14) were treated with 
LPS. mRNA and enzyme activity expression levels of important components of L-carnitine 
homeostasis were evaluated at 3 h and 16 h post injection to capture early mRNA expression 
changes (3 h) and changes in enzyme activity that takes time to occur (16 h) following the 
inflammatory stimulus. The results section is divided into two parts: i) Ontogeny of L-carnitine 
homeostasis, and ii) Effect of inflammation on L-carnitine homeostasis. 
 
3.1 Ontogeny of L-Carnitine Levels, Octn2, Tmlh and Bbh 
 
The ontogenesis of critical components of the L-carnitine homeostasis was examined by 
evaluation of serum and heart free L-carnitine concentration as well as mRNA expression of 
Octn2, Bbh and Tmlh in different tissues of rat pups of different postnatal ages. Compared to 
PD3, (average 20 mmol/L), serum free L-carnitine concentrations were significantly higher at 
PD7, (average 30 mmol/L), which was further increased to an average value of 34 mmol/L at 
PD14 (Figure 3.1). Heart free L-carnitine levels also increased with postnatal age, but showed a 
significant increase between PD7 and PD14 (Figure 3.2).  
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Figure 3.1 Mean ± SEM free L-carnitine concentration in rat serum (n = 4) at postnatal day 3, 7 
and 14 (3 hour control – white bar; 3 hour treatment – light grey bar; 16 hour control – dark grey 
bar; 16 hour treatment – black bar).  L-Carnitine concentration was determined using HPLC-UV 
as described in the text. Two-way ANOVA with Bonferroni post hoc test was used for the 
comparisons between treatment groups and one-way ANOVA was used for the comparisons 
between ages and treatment. Bars with an asterick indicate significant difference relative to 
control, P<0.05. 
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Figure 3.2 Mean ± SEM free L-carnitine concentration in rat heart samples (n = 4) at postnatal 
day 3, 7 and 14 (3 hour control – white bar; 3 hour treatment – light grey bar; 16 hour control – 
dark grey bar; 16 hour treatment – black bar). L-Carnitine concentration was determined using 
HPLC-UV as described in the text. Two-way ANOVA with Bonferroni post hoc test was used 
for the comparisons between ages and treatment and bars with astericks indicate significant 
difference relative to controls, P<0.05. 
 
Heart and kidney Octn2 expression was increased with increasing postnatal age. Kidney 
and heart Octn2 mRNA expression were increased 8- and 13-fold between PD 3 and PD 14, 
respectively, although increases in expression in heart between PD 3 and PD 7 were not 
statistically significant (Figure 3.3). In the intestine, Octn2 expression was low at PD 3 and 
expression decreased insignificantly at PD 7 (Figure 3.3). Kidney and liver Tmlh mRNA 
expression increased between PD 3 and PD 14 (Figure 3.4). Kidney Tmlh mRNA expression 
significantly increased 24-fold between PD 3 and PD 7, whereas liver Tmlh mRNA expression 
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significantly increased postnatally (Figure 3.5). Bbh mRNA expression levels were increased 
insignificantly between PD 3 ad PD 7; however, significant increase (35-fold), in Bbh mRNA 
expression was found at PD 14. Bbh enzyme activity showed 2.5 and 5 times increase at PD 7 
and PD 14 relative to PD 3, respectively (P<0.05) (Figure 3.5 B). 
 
 
Figure 3.3 Mean ± SEM organic cation/carnitine transporter 2 (Octn2) (PD 3 – white bar; PD 7 
light grey bar; PD 14 – black bar) mRNA expression levels in rat pup kidney, heart, and intestine 
at different postnatal ages (n=4). mRNA expression was normalized to ß-actin. Bars with no star 
indicate no significant difference relative to PD 3, P<0.05. 
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Figure 3.4 Mean ± SEM Tmlh (PD 3 – white bar; PD 7 light grey bar; PD 14 – black bar) mRNA 
expression levels in rat pup kidney and liver at different postnatal ages (n=4). mRNA expression 
was normalized to ß-actin. Bars with no star indicate no significant difference relative to PD 3, 
P<0.05.  
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Figure 3.5 Mean ± SEM Bbh (PD 3 – white bar; PD 7 light grey bar; PD 14 – black bar) mRNA 
expression levels in rat pup liver (A) and liver Bbh activity (B) at different postnatal ages (n=4). 
mRNA expression was normalized to ß-actin. Bars with no star indicate no significant difference 
relative to PD 3, P<0.05. 
 
3.2 TNF-α Levels: 
 
To confirm the induction of inflammation, serum samples obtained from LPS and saline 
treated rat were evaluated for TNF-α activity. Serum TNF-α at 3 h was tested in treatment and 
control animals (Figure 3.6). Significant increases in serum TNF-α concentration were observed 
at 3 hours post LPS administered treatment groups at all age groups of rats. The TNF-α 
concentration was increased approximately 25-, 22-, and 42-times in 3 hours post LPS 
administered in PD 3, PD 7, and PD 14 rat pups, respectively.  
B 
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Figure 3.6 Mean ± SEM TNF-α concentrations in rat serum (Control Group – white bar; 
Treatment Group – grey bar). Student T-test was used for the comparisons between treatment 
groups and bars with three astericks indicate significant difference, P<0.05. 
 
3.3 Effect of acute inflammation on ontogeny of L-carnitine homeostasis mechanism 
 
LPS administration caused changes in free L-carnitine levels in serum and heart (Figure 
3.1). Serum free L-carnitine levels were significantly decreased in all LPS treated groups of all 
postnatal age rat pups. LPS caused no change in free L-carnitine levels in 3 h post LPS 
administration treatment group of PD 14 rat pups. Free L-carnitine levels in heart were 
significantly decreased in all LPS treated groups of all postnatal age rat pups. LPS caused no 
change in heart free L-Carnitine levels in 3 h post LPS administration treatment group of PD 3 
rat pups (Figure 3.2). 
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3.4 Effect of LPS on mRNA expression of Octn2 transporter in kidney, liver, heart and 
intestine 
 
To examine the ontogenesis of critical components of the L-carnitine homeostasis pathway 
we conducted an mRNA expression of one of the main components of the homeostasis pathway, 
Octn2, in different tissues of rat pups at 3 h and 16 h post LPS administration at PD 3, PD 7 and 
PD 14. LPS treatment caused a significant decrease in kidney, heart and intestinal Ocnt2 
expression (p<0.05) (Figure 3.7). Kidney Octn2 expression was decreased by 26, 25 and 24 
percent relative to control in 16 h post LPS administration in rats at PD 3, PD 7, and PD 14, 
respectively (Figure 3.7 A). Except in the 3 h post LPS administration treatment group at PD14 
rat pups, mRNA levels decreased by 20 percent, Octn2 expression levels in kidney did not show 
statistically significant changes in any remaining age groups (Figure 3.7 A). Intestinal Octn2 
expression was decreased by 45, 75 and 60 percent at 3 h post LPS administration in PD 3, PD 7 
and PD 14 rat pups, respectively (Figure 3.7 B). Intestinal Octn2 expression is decreased by 60, 
75 and 90 percent in 16 h post LPS administration in rat pups at PD 3, PD 7 and PD 14, 
respectively. Octn2 expression levels in heart and intestine were decreased significantly in 3 h 
post LPS administration and 16 h post LPS administration treatment groups of all postnatal age 
groups (figure 7.3 C). Heart Octn2 expression was decreased by 25, 50 and 27 percent at 3 h post 
LPS administration in rat pups at PD 3, PD 7 and PD 14, respectively (Figure 7.3 C). Heart 
Octn2 expression was decreased by 40, 80 and 70 percent at 16 h post LPS administration in rat 
pups at PD 3, PD 7 and PD 14, respectively (Figure 3.7 C). Except in the 16 h post LPS 
administration treatment group for PD 7 and PD 14, where a 64 percent decrease in Octn2 
mRNA expression levels was observed in liver, expression changes were not statistically 
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significant in both treatment groups (3 h post LPS administration and 16 h post LPS 
administration) at all postnatal ages (Figure 3.7 D).  
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Figure 3.7 Mean ± SEM organic cation/carnitine transporter (Octn2) mRNA expression (white 
bar – control; light grey bar – 3 h post LPS administration; dark grey bar – 16 h control; black 
bar – 16 h post LPS administration) in rat kidney (panel A), intestine (panel B), heart (panel C), 
and liver (panel D) at postnatal day 3, 7 and 14 (n = 4). mRNA expression was normalized to β-
actin and fold difference (FD) was determined by using 2-ΔΔCT method. Two-way ANOVA with 
Bonferroni post hoc test was used for the comparisons between ages and treatments and bars 
with the same symbols indicate no significant difference, P<0.05. 
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3.5 Effect of LPS on mRNA expression and activity of Bbh in liver 
 
LPS caused changes in Bbh mRNA expression levels and Bbh enzyme activity in all 
treatment groups (P<0.05) (Figure 3.8). Liver Bbh mRNA expression was decreased 
significantly (p<0.05) in all LPS treatment groups of all age groups, except in the 3 h post LPS 
treatment group at PD 3 and PD 14 (p>0.05) (Figure 3.8 A). Liver Bbh mRNA expression was 
significantly decreased by 32 and 25 percent in the 16 h post LPS treatment groups at PD 3 and 
PD 14, respectively, while it was significantly decreased 26 and 95 percent in both 3 h and 16 h 
post LPS treatment groups of PD 7, respectively. LPS caused no changes in liver Bbh activity in 
all treatment groups at PD 14 (Figure 3.8 B). At PD 3, LPS caused a significant decrease in Bbh 
activity in 3 h post LPS administration group (57 %) and in the 16 h post LPS administration 
treatment group (73 %). At PD 7, LPS only significantly decreased the 16 h post LPS 
administration treatment group (44 %) (Figure 3.8 B). 
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Figure 3.8 Mean ± SEM rat liver gamma-butyrobetaine hydroxylase (Bbh) (A) mRNA 
expression and (B) activity at postnatal day 3, 7 and 14 (n = 4) (white bar – control; light grey 
bar – l3 h post LPS administration; dark gray bar – 16 h control; black bar – 16 h post LPS 
administration). mRNA expression was normalized to β-actin and fold differences (FD) were 
determined by using 2-ΔΔCT method. Bbh activity was measured by quantifying the conversion of 
γ-butyrobetaine to L-carnitine by HPLC-UV. Two-way ANOVA with Bonferroni post hoc test 
was used for the comparisons between ages and treatments and bars with the same letters 
indicate no significant difference, P<0.05. 
 
3.6 Effect of LPS on mRNA expression and activity of Tmlh in liver and kidney 
 
LPS administration significantly decreased liver Tmlh mRNA expression levels in all age 
groups (P<0.05) (Figure 3.9 A). Liver Tmlh mRNA expression was decreased by 40 and 85 
percent at 3 h and 16 h post LPS administration at PD 3, respectively. Liver Tmlh mRNA 
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expression was decreased by 30 and 90 percent at 3 h and 16 h post LPS administration at PD 7, 
respectively. Liver Tmlh mRNA expression was decreased by 60% at 3 h post LPS 
administration at PD 14. LPS caused no changes in kidney Tmlh mRNA expression in all 
treatment groups at PD 3 and at 3 h post LPS treatment group at PD 7 (Figure 3.9 B). Tmlh 
mRNA expression in kidney was decreased by 45% at 3 h post LPS administration in in 16 h 
post LPS administration treatment groups at PD 3 by 35% in 16 h post LPS administration 
treatment groups at PD 14, and by 90% at 16 h post LPS administration treatment group at PD 7 
(Figure 3.9 B). 
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Figure 3.9 Mean ± SEM mRNA expression of Tmlh in rat pups (in liver (A) and kidney (B)) at 
postnatal day 3, 7, and 14 (n = 4) (white bar – control; light grey bar – 3 h post LPS 
administration; dark gray bar – 16 h control; black bar – 16 h post LPS administration treatment). 
mRNA expression was normalized to β-actin and fold difference (FD) was determined by using 
2-ΔΔCT method. Two-way ANOVA with Bonferroni post hoc test was used for the comparisons 
between ages and treatment bars with astericks indicate significant difference relative to control, 
P<0.05.   
 
3.7 Effect of LPS on mRNA expression and activity of Ct1b and Cpt2 in heart 
 
LPS caused a significant increase (3.6 fold in 3 h post LPS administered group and 3.8 fold 
in 16 h post LPS administered group) in heart Cpt1b mRNA expression levels at PD 7 (Figure 
3.10 A). Except in PD 7 treatment groups, heart Cpt1b mRNA expression levels did not show 
significant changes at all postnatal ages (figure 3.10 A). LPS caused no significant changes in 
heart Cpt2 mRNA expression in any of the treatment groups (figure 3.10 B)). 
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Figure 3.10 Mean ± SEM mRNA expression of heart carnitine palmitoyltransferase 1b (Cpt1b) 
(A) and carnitine palmitoyltransferase 2 (B) in rat pups at postnatal day 3, 7, and 14 (n = 4) 
(white bar – control; light grey bar – 3 h post LPS administration; dark grey bar – 16 h control; 
black bar – 16 h post LPS administration). mRNA expression was normalized to β-actin and fold 
difference (FD) was determined by using 2-ΔΔCT method. Two-way ANOVA with Bonferroni 
post hoc test was used for the comparisons between ages and bars with astericks indicate 
significant difference relative to control, P<0.05.   
 
LPS caused no significant changes in heart Cpt1b and Cpt2 enzyme activity levels at PD 3, PD 7 
and PD 14. (Figure 3.11). 
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Figure 3.11 Mean ± SEM enzyme activity of heart carnitine palmitoyltransferase 1b (Cpt1b) (A) 
and carnitine palmitoyltransferase 2 (Cpt 2) (B) in rat pups at postnatal day 3, 7, and 14 (n = 4) 
(white bar – control; light grey  bar – 3 h post LPS administration; dark gray – 16 h control; 
black bar – 16 h post LPS administration treatment). Two-way ANOVA with Bonferroni post 
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hoc test was used for the comparisons between ages and treatment and bars with asterisks 
indicate significant difference, P<0.05.   
 
3.8 Effect of LPS on high energy phosphate substrate concentration in heart 
  
Significant changes in heart creatine phosphate was observed in 16 h post LPS 
administered treatment groups in all age groups of rats. However, significant changes in heart 
creatine, ATP, and ADP levels were not observed in LPS treated rat pups. At 16 h post LPS 
administration, creatine phosphate was decreased by 34% in PD 3 rat pups, 25% in PD 7 rat 
pups, and 30% in PD 14 rat pups (Figure 3.12). 
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Figure 3.12 Mean ± SEM heart high-energy phosphate substrate concentration in rat pups at 
postnatal day 3, 7 and 14 (n = 4) (white bar – control; light grey bar – 3 h post LPS 
administration; dark gray bar – 16 h control; black bar – 16 h post LPS administration treatment). 
The heart high energy phosphate substrate levels including creatine (Cr), creatine phosphate 
(CrP), ATP, and ADP were measured with HPLC-UV method as described by Olkowski et al. 
[24]. Two-way ANOVA with Bonferroni post hoc test was used for the comparisons between 
ages and treatment and bars with an asterisk indicate significant difference, P<0.05. (Cr – 
creatine; CrP -creatine phosphate). 
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Chapter 4 
4. Discussion 
The nutritional requirements for normal growth and development are often affected by 
ontogenic processes of several nutritional pathways during postnatal development. The 
developmental changes in these nutrient homeostasis pathways are usually genetically 
programmed (181). However, these processes can be affected by exogenous factors such as 
dietary components, environmental factors including chemicals, pathological conditions, and 
therapeutic drugs.  Since my laboratory is interested in understanding how external factors 
influence the ontogeny of important nutrient homeostatic processes, my thesis work involved the 
evaluation of the effect of acute inflammation on the developmental maturation of L-carnitine 
homeostasis pathways.  
I used the rat in my work as a previous study in the lab provided the ground work for the 
ontogeny of a number of L-carnitine homeostasis mechanisms in the rat (136). Previous studies 
on evaluation of key pathways in the L-carnitine homeostasis pathway provided the basis from 
which I conducted further evaluations regarding the effects of pathological factors on L-carnitine 
status during postnatal development and possible long-term consequences of any disturbance in 
the normal ontogeny of these pathways (182). My laboratory’s previous study did not assess 
potential gender effects on the ontogeny of and effects of a drug on L-carnitine homeostasis 
pathway development. Ethical considerations precluded an evaluation of gender effects in the 
current study as more that twice as many animals would be necessary in the study design. This 
may represent an important limitation of study design that we acknowledged at the start of the 
study. The information gleaned from my thesis work will begin the journey in understanding 
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how exogenous factors may alter maturation and the possible long-term consequences of such 
alterations.  
As mammalian foetuses transition to extrauterine life, the umbilical supply of essential 
nutrients is cut off, including glucose which serves as the major energy fuel of the fetus. During 
the neonatal period, fatty acid oxidation becomes the main source of energy for a number of 
tissues (183). A sufficient supply of L-carnitine is essential for efficient mitochondrial fatty acid 
utilization, as this nutrient facilitates the movement of long-chain fatty acids across the 
mitochondrial membrane making them available for β-oxidation. The foetus liver stores 
significant levels of L-carnitine during late gestation, and such stores assure adequate levels in 
the immediate postpartum period (136). However, these tissue stores quickly deplete, and the L-
carnitine homeostasis mechanisms begin to undergo maturational changes to ensure the 
physiological system has adequate L-carnitine to meet the energy needs of various tissues.   
Postnatal increases in serum free L-carnitine is reported in the literature and these increases 
correlate with maturation of a number of enzymes and transporter systems that critically 
determine L-carnitine levels in the body (136). Previous studies on evaluation of key pathways in 
the L-carnitine homeostasis pathway (136) provided a basis from which we conducted further 
evaluations regarding the effects of inflammation on L-carnitine status during postnatal 
development and this concept may be extended to evaluate possible long-term consequences of 
any disturbance in the normal ontogeny of these pathways. This corroboration was essential as it 
shows ability to reproduce previous work in the laboratory and suggests that outcomes of my 
evaluations regarding LPS administration have important value. Since very little work has been 
published in the literature regarding the effects of inflammation on the transporters and ontogeny 
of L-carnitine homeostasis, I have no basis for comparison. One study conducted in my 
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laboratory evaluated the effect of inflammation on activity of nutrient transporter (manuscript 
submitted), but my thesis work represents novel information. I was not able to repeat the 
evaluations to ensure reproducibility of experimental outcomes during my graduate program. 
Lower serum free L-carnitine levels in the early postnatal period is, in part, due to the 
limited capacity for endogenous biosynthesis by the young neonate (135).  As noted in other 
studies (90), my study showed that hepatic γ-Bbh and Tmlh mRNA expression and γ-Bbh 
activity was significantly lower at early postnatal development in rat pups, consistent with the 
lower serum free L-carnitine concentrations observed at younger neonatal ages.  The increase in 
serum free L-carnitine levels in rat pups with advancing age was matched with the maturation of 
hepatic γ-Bbh and Tmlh, suggesting that enhancements in endogenous L-carnitine biosynthesis 
contributes, in part, to the postnatal increase in L-carnitine levels in the body. However, 
evaluation of other critical mechanisms responsible for L-carnitine homeostasis suggests that 
maturation of other processes, namely renal reabsorption of L-carnitine, additionally contributes 
to the postnatal rise in serum L-carnitine. 
Absorption of dietary sources of L-carnitine requires the function of several transporter 
systems expressed at the gastrointestinal epithelial barrier. Expression of duodenal Octn2 did not 
change with postnatal development. This was not consistent with increases in Octn2 expression 
noted in the literature, but could be the result of different rat strains (Sprague Dawley vs. Wistar) 
or different portion of the small intestine (jejunum or ileum vs. duodenum) (143). I did not 
evaluate protein expression levels nor measure transporter activity in the intestine; hence, I 
cannot conclude with certainty whether the lack of changes in mRNA expression with 
development may suggest that the absorptive capacity of L-carnitine by these transporter systems 
remains unchanged.  
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In my study renal Octn2 expression was increased during postnatal development in the rat, 
which was consistent with my laboratory’s previous study and the literature (184). The increase 
in renal Octn2 expression was matched with the postnatal increase in serum L-carnitine levels. 
Hence, in addition to maturation of endogenous biosynthesis, maturation of renal Octn2 also has 
a significant role in the postnatal pattern of serum L-carnitine development. Overall, our data 
suggests the developmental changes in hepatic γ-Bbh and Tmlh expression and renal Octn2 
expression may contribute to the postnatal increase in serum L-carnitine levels.  
The highest concentrations of L-carnitine are primarily found in serum (136). In my study, 
heart L-carnitine levels increased during postnatal development (Figure 3.2). Evaluation of the 
expression of Octn2 in pup heart tissue also suggested that this postnatal increase corresponds to 
enhanced heart Octn2 expression with advancing postnatal age. The neonatal and adult heart 
relies on fatty acids as a principal energy substrate (185). Hence, L-carnitine has a significant 
role in energy production in neonatal cardiac tissue. The dramatic increase in fatty acid oxidation 
rates in early heart development after birth has been attributed to an increase in L-carnitine 
levels. Although we observed a significant increase in L-carnitine levels in the heart with 
advancing age of the neonate, cardiac ATP levels remained constant through postnatal 
development. My studies showed a trend towards increasing ATP levels but this was not 
significant. Interestingly, I found that Cpt1b and Cpt2 enzyme levels as well as creatine 
phosphate and creatine levels increased with postnatal development, which was consistent with 
my laboratory’s previous study (136). Unfortunately, I was unable to determine AMP levels with 
reliability due to HPLC assay interference as such information is important in understanding the 
energy charge of a tissue. These ontogenic changes suggest an increasing capacity of the heart to 
utilize fatty acids for energy production with advancing neonatal age. This maturation does 
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suggest that exogenous impacts (such as disease and drugs) that influence these systems, either 
through direct inhibition or altered genetic regulation, may have significant impacts on the ability 
of the heart to generate ATP through fatty acid oxidation. The overall significance of such 
developmental changes is not clear and requires investigation. 
In addition to my evaluation of the ontogeny of L-carnitine homeostasis mechanisms, the 
main objective of the work carried out in my thesis was to evaluate the effect of inflammation, a 
significant clinical factor, on the ontogeny of L-carnitine homeostasis mechanisms in neonates. 
The pathogenesis of inflammation due to the administration of LPS may involve different 
inflammatory stimuli, which in turn may alter the natural ontogenic process of L-carnitine 
homeostasis. Specifically, inflammation-mediated alteration in the expression and function of 
Octn2, enzymes involved in endogenous biosynthesis, and the enzymes involved in 
mitochondrial shuttling of acylcarnitines may have significant consequences on serum and tissue 
levels of L-carnitine and on ability of organs to utilize fatty acids for ATP generation. In my 
study, I conducted a systematic comparison of the gene expression and activity, where possible, 
of Octn2, Bbh, Tmlh, Cpt 1b and Cpt 2 enzymes between control and LPS treated rat pups at 
three different postnatal ages. LPS is a commonly employed substance to elicit an inflammatory 
response (186), and I utilized a neonatal rat inflammatory model well established in the literature 
to meet this objective (173). We have used SD rats at postnatal day 3, 7 and 14, as these ages 
provide several advantages when monitoring the ontogenic changes of L-carnitine mechanisms. 
In the rat, endogenous biosynthesis matures at PD 8 (91, 187, 188). Hence, these age groups 
capture the ontogeny of the L-carnitine biosynthetic enzymes and other key L-carnitine 
homeostasis mechanisms prior to and following maturation of endogenous L-carnitine 
biosynthesis. My findings can be used to postulate and predict the potential outcomes of the 
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effect of inflammation on ontogenic mechanisms. However, my work cannot elucidate the exact 
impact of the changes caused by an inflammatory stimulus and their overall contribution to L-
carnitine homeostasis during development and further studies will be required to clarify 
contributions. 
Several findings were generated in my work, which are summarized in the following 
discussion.  My thesis work suggests that development of inflammation in neonates can alter the 
normal ontogeny of L-carnitine homeostasis. My findings suggest that inflammation has 
statistically significant effects on the main elements of L-carnitine homeostasis and that 
inflammation is likely to have significant clinical relevance and relevance to the overall 
development of the neonate as it proceeds towards adult life stages. 
Acute inflammation caused a significant decrease in free L-carnitine levels in serum and 
heart tissue. Based on the results obtained from Octn2 gene expression experiments, the decrease 
in mRNA expression levels of renal and intestinal Octn2 might be the principle cause of 
depletion of serum and heart L-carnitine levels. Renal reabsorption of L-carnitine from the 
urinary filtrate plays a significant role in maintenance of L-carnitine levels in the body. Almost 
95% of the excreted L-carnitine is reabsorbed by transporters expressed in the proximal tubules 
of the kidney with Octn2 as the principal transporter involved in this process (189, 190). In my 
study renal Octn2 expression decreased following LPS administration in the rat pup. The 
decrease in renal Octn2 expression corresponded strongly with decrease in serum L-carnitine 
levels suggesting that renal Octn2 plays a significant role in the postnatal pattern of serum L-
carnitine development. In addition to kidney Ocnt2 levels, gene expression levels of intestinal 
Octn 2 might be an additional cause of the reduction in serum L-carnitine concentration.  
Absorption of dietary L-carnitine requires the function of several transporter systems expressed 
70 
 
at the gastrointestinal epithelial barrier. Expression levels of duodenal Octn2 were decreased 
with LPS administration and this might result in the decrease in L-carnitine absorption from the 
milk following suckling. The decrease in heart Octn2 gene expression (in conjunction with lower 
serum L-carnitine levels) likely explains the reduction in heart L-carnitine levels with LPS 
administration, since Octn2 mediates the uptake of L-carnitine into heart tissue.  
My study corroborated previous investigations in that hepatic γ-Bbh mRNA expression and 
activity levels were low in the first days of life and matured with postnatal age (187, 188).  The 
maturation of hepatic γ-Bbh contributes to the postnatal increase in L-carnitine levels in the 
body. However, my study on the effect of acute inflammation suggests that maturation of hepatic 
γ-Bbh was disturbed and this might play a significant role in the reduction of serum L-carnitine 
levels. Although inflammation caused alterations in hepatic γ-Bbh mRNA levels at all three 
postnatal age groups, hepatic γ-Bbh enzyme activities were not affected at PD 14. These results 
correlate with the serum L-carnitine levels at PD 14 post LPS administration suggesting that the 
γ-Bbh enzyme had matured to maximum levels prior to PD 14. Hepatic and renal Tmlh mRNA 
expression levels were significantly lower at early postnatal development in rat pups and 
matured with postnatal age. My study on the effect of acute inflammation suggests that 
maturation of hepatic and renal Tmlh mRNA expression changed with an inflammatory stimulus 
at all postnatal age groups. Without evaluation of Tmlh activity, it is difficult to speculate 
whether reduction in Tmlh mRNA expression translates into reductions in Tmlh activity. The 
literature suggests Tmlh is a rate-determining enzyme in the biosynthesis of L-carnitine (191). 
Consequently, any reduction in Tmlh activity following inflammation may result in a lowered 
capacity to synthesize L-carnitine de novo.  This could contribute to inflammation mediated 
reductions in serum L-carnitine levels noted in my study. 
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Since LPS causes differential changes in transporters that mediate the transport of critical 
substrates used in the generation of cellular energy, I next evaluated whether such changes could 
result in differences in mitochondrial ATP production. LPS significantly decreased CrP and 
caused a non-significant decrease in ADP levels. Reductions in CrP is generally considered a 
pathological indicator. Interestingly, in a previous study in the lab, chronic cefepime 
administration (cefepime is a competitive inhibitor of Octn2) caused histopathological changes 
in the heart at an early postnatal age, but not at older postnatal ages (136). This study also 
indicated reductions in CrP with chronic cefepime administration. Consequently, reductions in 
heart CrP may suggest early pathological changes with LPS administration. Furthermore, the 
decreased expression of Octn2 in LPS treated rats may suggest a reduction in the intracellular 
supply of L-carnitine and reduction in fatty acid oxidation. To maintain cellular ATP levels, 
heart tissue may have to increase glycolysis (and thus oxidative phosphorylation) to compensate 
for the lowered energy production by fatty acid oxidation. This may explain the minimum 
changes in ATP levels in LPS challenged rats.  
         Based on the results obtained from the present study, inflammation shows time dependent 
effect on the ontogeny of L-carnitine homeostasis in early neonatal stages. The overall results 
from the current study suggests that LPS induced inflammation has profound effect on ontogeny 
of L-carnitine homeostasis in early postnatal stages (PD 3 and PD 7). Since most of the elements 
in L-carnitine homeostasis are undergoing ontogeny before PD 14, inflammation caused less 
effects on PD 14 rats when compared to earlier postnatal age groups. 
L-carnitine homeostasis pathways underwent significant ontogenesis during postnatal 
development in the rat. However, the exact relationship between these pathways and their 
contribution to L-carnitine homeostasis during development is not completely known and further 
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studies are required to clarify their contributions. Such a clarification is necessary to understand 
the impact of exogenous and endogenous factors on L-carnitine status during development. 
 
4.1 Future Directions  
 
• The individual role of pro-inflammatory cytokines in LPS induced inflammation and its 
role in modulating the transporter expression at different stages of L-carnitine 
ontogenesis will be known by performing in vitro studies with radiolabelled substrates. 
• More experiments should be carried out to estimate the time required for translational 
changes in mRNA to provide a clearer picture on dosing and time elapse in similar 
experiments in future. 
• Experiments to assess cardiac oxygen consumption and high energy substrate levels 
should be carried for understand how inflammation modulates substrate energy levels and 
L-carnitine dependent energy producing pathways at the molecular level.  
• Radiolabelled studies are required to assess the Octn2 transporter activity in heart and 
kidney to determine whether inflammation-mediated reduction in transporter mRNA 
expression correlates with reduction in transporter activity.  
• In the neonate, my work suggested that inflammation resulted in changes in L-carnitine 
homeostasis pathways depending on timing and duration of inflammation to postnatal 
age. However, whether these changes are permanent or transient are unknown. Future 
studies are needed to investigate the potential for metabolic programming of L-carnitine 
and other nutrient homeostasis pathways following inflammation and the possible long-
term consequences of such interactions on the risk for adult onset disease. 
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• Separate experiments of similar kind should be conducted on male and female animals to 
classify unknown functional differences between the two genders. 
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